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ABSTRACT
Some cetaceans bioaccumulate substantial concentrations of halogenated aromatic
hydrocarbons CHAH) in their tissues, but little is known about the effects of such burdens
on cetacean health. 2,3,7,8-Tetrachlorodibenzo-p-dioxin CTCDD) and related HAH cause
toxicity via activation of the aryl hydrocarbon receptor CAHR), a member of the bHLH-
PAS family of transcription factors. Differences in AHR structure and function are
known to contribute to species-specific differences in susceptibility to HAH toxicity, and
targets for HAH toxicity are related to the tissue-specific expression of AHR. The goal
of these studies was to ascertain the potential for HAH effects in cetaceans by
characterizing the AHR from the beluga, Delphinapterus leucas. The beluga AHR was
characterized by its molecular structure, capacity for ligand binding, structure-binding
relationships with various classes of HAH, as well as tissue-specific expression.
These results show that: 1) in an in vitro system, the beluga AHR possesses
binding affinities similar to AHRs of other mammals that are considered sensitive to
toxic effects of HAH, 2) Structure-activity relationships are consistent with a common
mechanism of coplanar HAH action among cetaceans and rodent species, and 3) the
AHR protein is expressed in many tissues of the beluga, and is present at high levels in
lymphoid organs, liver and lung. Together, these data suggest that cetaceans can be
considered sensitive to the action of coplanar HAH. Further, using in vitro expressed
proteins is a promising approach for addressing molecular and biochemical questions
about PHAH toxicity in endangered and protected species where logistical and ethical
concerns preclude testing in live animals.
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Halogenated aromatic hydrocarbons (HAR) in the environment
Halogenated aromatic hydrocarbons (HAH) are thennodynamically stable
chemicals that elicit a number of biochemical and toxic responses. HAH include the
dibenzo-p-dioxins (e.g. TCDD), dibenzofurans (e.g. TCDF), and polychlorinated
biphenyls (PCBs)(Figure 1). Although most western countries banned new and open uses
of PCBs in the 1970's, PCB influx into the environment continues. PCBs are still
permitted for use in large transistors, capacitors, and hydraulics in the U.S. In developing
countries, PCB use and disposal is not well documented (AMAP, 1998).
HAHs reach the marine environment from many sources. A major source of PCBs
is disposal of PCB-containing machinery. Transistors, capacitors, and vacuum pumps are
disposed in landfills, slow degradation allows PCBs to leech into ground water, and heat
from waste decomposition causes PCBs to volatilize and distribute atmospherically
(McClure, 1976). Chlorinated dioxins and furans reach the environment as minor
components of other organochlorine mixtures as a byproduct of manufacture or fonned
during use or disposal. Processes such as paper bleaching and waste burning are common
sources of chlorinated dioxins. Brominated dioxins and furans are fonned by burning
flame retardant substances, and though these are less persistent, they are potentially more
toxic to freshwater fish embryos than the chlorinated species (Hornung et al., 1996).
Oceanic and atmospheric circulation are the likely modes by which HAHs are
transported to regions where there is little human activity such as the Arctic, where
organisms display surprisingly high concentrations of chlorinated hydrocarbons
considering their remote location (Wade et al., 1997). Although legislation may limit
14
HAH use in certain parts of the globe, the past and current use of organohalogens leave no
marine environment pristine.
Cetaceans are exposed to HAH
Marine mammals accumulate large concentrations of HAH in tissue. As top
predators in the coastal environment that depend morphologically and physiologically on
huge lipid reserves, odontocete cetaceans are ideal reservoirs for hydrophobic and
metabolically resistant HAH. In certain populations, PCBs can reach very high
concentrations. For example, PCBs as high as 500 flg/g, 50-fold higher than what was
observed as sufficient to cause reproductive and hormonal dysfunction in terrestrial
mammals, have been observed in beluga adipose tissue (Martineau et al., 1987).
HAH accumulation in odontocetes is known to be sex and age-dependent. HAH
patterns in 13 species of odontocetes show no sex difference in HAH accumulation rates
among immature animals. However, HAH blubber burdens in females decrease
dramatically after the first offspring, and fluctuate around a lower mean concentration
during reproductive years, while males accumulate HAH throughout life (O'Shea, 1999).
Exposure concentrations of persistent organic pollutants may be highest during fetal and
neonatal development. Tanabe et al. estimated that a mother spinner dolphin (SteneUa
coeruleoalba) could transfer 4-10% of her PCB burden transplacentally (Tanabe &
Tatsukawa, 1992). Placental transfer appears to. be structure-dependent. An examination
of a neonate beluga and its mother showed preferential transfer of lower chlorinated PCBs
and other organochlorines relative to more highly substituted congeners (Gauthier et aI.,
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1998). Measurements in fetal and neonatal pilot whales (Globicephala melas) indicate
that the organochlorine pesticide DDT is more readily transferred across the placenta than
PCBs. However, DDT and PCBs are transferred equally via lactation (Borrell et al.,
1996). Lactation is clearly the more significant route of HAH transfer; Cockcroft et al.
(1989) predicted that a mother bottlenose dolphin can transfer up to 80% of her PCB
burden to her firstborn calf (Cockcroft et al., 1989). These data indicate not only that
cetaceans are exposed during important developmental periods, but also reveal a
mechanism for retaining a significant portion of HAH in the population by passing
burdens on to subsequent generations.
Evidence for contaminant-related health effects in cetaceans
There is evidence from some cetacean populations suggesting that HAH burdens
can increase susceptibility to disease. After a major morbillivirus epizootic that affected
striped dolphins (SteneUa coeruleoalba), the animals that succumbed to the virus had
significantly higher PCB burdens in the blubber than did animals from the same stock that
survived the mass mortality event (Aguilar & Borrell, 1994; Borrell et al., 1996). In a
study of harbor porpoise that inhabit the waters of the u.K., PCB burdens were
significantly higher in animals that died from disease (stranded) compared to animals that
died from trauma (bycatch) (Jepson et al., 1999).
Beluga that inhabit the St. Lawrence Estuary are an isolated stock of -500
(Kingsley, 1998) that are heavily burdened with contaminants, including HAH (Martineau
et al., 1987) (Figure 2). This population was severely decimated when it was believed that
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beluga competed with the fishermen for cod, and culling by the public was encouraged.
Since culling was halted in the 1970's, the population has not recovered (Bailey & Singer,
1995). Compared with High Arctic stocks, the St. Lawrence beluga suffer a low rate of
reproduction and a high rate of disease. Within the diverse suite of pathologies observed
in the St. Lawrence population, three categories of health problems have emerged to cause
great concern. The first is a high incidence of tumors, and cancer in particular. At least
12 cases of malignant tumors have been reported since 1982 (Figure 3). These tumors
originate in several tissue types, but these beluga seem particularly susceptible to cancer
arising from the papilloma virus. Increased cancer susceptibility can be indicative of
suppressed innate and cellular immunity, and/or higher exposure to carcinogens such as
certain HAHs and polycyclic aromatic hydrocarbon metabolites. These beluga also
appear to succumb easily to infections by bacteria that are considered to be only mildly
pathogenic, including pneumonia, mammary mastitis, and other opportunitic infections
that have accounted for organ failure and death in some individuals (Deguise et al., 1995;
Martineau et al., 1994; Martineau et aI., 1988). Also of serious concern is a very low rate
of reproduction that is coincident with low pregancy rate, low ovarian activity, and
dystocia (death during calving) (Bailey & Singer, 1995).
Lahvis et al. (1995) determined that the partial loss of proliferative response of
bottlenose dolphin (Tursiops truncatus) lymphocytes to mitogens was proportional to total
PCB and DDT concentrations in the blood (Lahvis et al., 1995). Although no controlled
study of immune dysfunction in cetaceans has been possible to date, a semi-field
experiment on harbor seals has revealed a potentially significant cause and effect
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relationship between HAH and the immune system. One group of seals was fed herring
from the highly contaminated BaltiC Sea, and the control group was fed herring from the
relatively uncontaminated North Atlantic. The seals fed Baltic fish exhibited a suppressed
immune response relative to controls. The parameters measured included proliferative
response to mitogens, natural killer cell activity assays, delayed-type hypersensitivity to
ovalbumin following subdermal injection, and a lower titer of circulating ovalbumin
antibodies (Deswart et al., 1995; DeSwart et al., 1994; Ross et al., 1995). The extent of
these responses correlated inversely to projected dioxin equivalents measured in blubber
biopsies of these seals. Since the T cell response is necessary in viral defense, these
authors suggest that HAH exacerbated the outbreaks of morbillivirus in common seals of
the Baltic Sea (Hall et al., 1992).
The Aryl Hydrocarbon Receptor (AHR)
AHR is required for toxic effects ofHAH
The growing list of HAH effects documented in terrestrial mammals include
immunosuppression, hepatotoxicity, carcinogenesis, reproductive/ developmental toxicity,
endocrine disruption, dermal toxicity, vitamin A depletion, wasting, and neural toxicity
(Schmidt & Bradfield, 1996). The discovery that these varied toxic effects were mediated
by a single receptor came from several lines of evidence: inbred mice that varied in
sensitivity to HAH, structure-activity relationships for HAH binding to AHR compared to
HAH induced effects, and finally, AHR knockout mice.
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The first clues indicating that toxicity of HAHs might be mediated by one locus
were from studies with inbred mice. The capacity for TCDD induction of aryl
hydrocarbon hydroxylase (CYF1A) activity varied according to mouse genotype; the
"non-responsive" DBN2 strain required at least 10 times the TCDD dose to elicit a
response equivalent to that in the "responsive" C57BL/6 strain (Poland & Glover, 1975).
Crossing the two strains yielded a strain with intermediate responsiveness and back-
crossing revealed that the ability to respond was dependent on one locus, named the Aryl
Hydrocarbon responsiveness (Ah) locus (Thomas et al., 1972). Poland et al. characterized
the putative gene product, a cytosolic protein that could bind to radiolabeled TCDD
(Poland et al., 1976). That allelic variation could account for the responsive and non-
responsive strains was confirmed when Poland's group later characterized four mouse
alleles, identifying the mutations that affected the ligand binding affinities of the AhRs
(Poland et aI., 1994).
Structure-activity relationships were also important for characterizing the role of
the AHR in HAH effects. The relative binding affinities of various HAH in liver cytosol
were in good agreement with the relative ability of HAH to induce aryl hydrocarbon
hydroxylase (ARR) activity (Poland & Knutson, 1982; Safe, 1994).
The quintessential piece of evidence that the AHR is necessary for TCDD toxicity
came from the generation of knockout mice. A sensitive indicator of AHR activation is
the induction of cytochrome P4501A (CYF1A). In three laboratories that generated AHR
knockout mice independently, none of these mice were capable of induction of CYP1A1
activity in response to TCDD (Fernandez-Salguero et al., 1995; Schmidt et al., 1996;
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Shimizu et al., 2000). Furthermore, these mice lacking the AHR (AhR/') are resistant to
TCDD induced toxicity at doses high enough to produce toxicity in wild type (AhR+1+)
mice and heterozygote (AhR+1') mice. The toxic effects examined in these strains included
thymic atrophy and hepatic abnormalities (Fernandez-Salguero et al., 1996)
hydronephrosis, and cleft palate (Mimura et al., 1997)[Peters, 1999] #5729].
AHR is a bHLH-PAS protein
Cloning of the AHR revealed that it is a member of the PAS Ceer ARNT ,$,im)
family of proteins (Burbach et al., 1992; Ema et al., 1992). The PAS proteins are found in
many different biochemical pathways whose common feature may be transduction of
signals from the cellular or organismal environment. Several are important in proper cell
timing and differentiation, including Drosophila Trachealess (Trh) in trachea
differentiation, and Single-minded (SIM) in neuronal development (Nambu et aI., 1991;
Wilk et al., 1996). Mammalian SIM2 (homologous to Drosophila SIM) is expressed
during embryonic development of the forebrain, and has been implicated in the expression
of the Down Syndrome phenotype in humans (Fan et al., 1996). Drosophila Period is
necessary for maintenance of the circadian clock (Jackson et al., 1986). Several other
PAS proteins are indicators of specific extracellular cues such as oxygen tension
(hypoxia-inducible factor-l (HIP) and aryl hydrocarbon nuclear translocator (ARNT)),
retinoic acid (steroid receptor coactivator-l), and xenobiotic compounds (AHR and
ARNT) (Hoffman et al., 1991; Li et al., 1996; Yao et al., 1996). Murine ARNT can
dimerize via its PAS domain with AHR, another ARNT, IDF, and Drosophila or mouse
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SIM in vitro (Probst et al., 1997; Swanson et al., 1995), suggesting a highly conserved
structural motif and potential for signaling "cross-talk".
Conservation of molecular structure in these PAS family members has aided
investigators in the classification of functional domains of these proteins (Gu et al., 2000).
The AHR-specific roles of these functional domains were characterized by deletion
analysis (Fukunaga et al., 1995) (Figure 4). The current model consists of a basic Helix-
Loop-Helix (bHLH) motif involved in HSP90 binding, dimerization with ARNT, and
DNA binding. The PAS domain is approximately 300 amino acids in length with two
degenerate repeats of approximately 50 amino acids, PAS A and PAS B. The PAS region
is involved in ligand binding, HSP90 binding, and dimerization. The C terminus is
important in transcriptional activation.
AHR signaling pathway and molecular biology
Much of our knowledge of AHR signaling has come from the examination of the
induction of CYP1A1 (Figure 5)(for reviews, see (Whitlock, 1999; Wilson & Safe,
1998)). The AhR complex at various stages of activation and inactivation is heteromeric
with several proteins. Two hsp90 proteins are associated with the AhR; they aid in proper
folding and maintaining conformation in the inactive state (Chen & Perdew, 1994; Heid et
ai., 2000). Enan and Matsumura showed that c-Src, a tyrosine kinase and oncogene, is a
component of the unliganded AhR complex in rodent liver and adipose tissue (Enan &
Matsumura, 1996). Three laboratories concurrently discovered an immunophilin-like
protein: a 37 kD protein cloned from a HeLa cDNA library (Ma & Whitlock, 1997) and
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a 37-8 kD protein cloned from a B cell cDNA library (Carver & Bradfield, 1997), now
termed AHR Interacting Protein (AlP)(Meyer et aI., 1998). These investigators suggest
that AlP is involved in a nuclear targeting signal.
Upon ligand binding, the ligand-hsp90-AHR complex translocates to the nucleus
and upon dimerization with ARNT, the AHR transforms to a DNA binding form; each
phase is most likely regulated by kinase activity. Translocation of the activated complex
to the nucleus depends on protein kinase C (Carrier et al., 1992; Chen & Tukey, 1996).
Dimerization with ARNT facilitates binding to particular enhancer sequences called
Dioxin Responsive Elements (DRE). DREs are found in the promoter regions upstream
of several ofthe AHR-inducible genes, including CYPIA1, CYPIB1, and glutathione S-
transferase Ya subunit. Transcription of the these genes involved in metabolism of
xenobiotic compounds completes the "adaptive response" (Schmidt & Bradfield, 1996)
AHR-dependent mechanisms a/toxicity
Unlike the induction of CYPIA1, the exact mechanisms of AHR-dependent
signaling in bona fide toxic responses are not as well understood. As stated earlier, the
AHR is a pleiotropic mediator of many dioxin-induced toxic endpoints. In this
discussion, I will attempt to summarize what is known about the role of the AHR and the
specific targets in two types of HAH-induced toxicity that appear to be most relevant to
cetaceans that are exposed to environmental contamination: cell cycle disruption and
immunosuppression. These mechanisms are not necessarily mutually exclusive.
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Cell cycle disruption The phosphorylation cascades initiated by AhR activation
by ligand appear to interfere with regulation of normal cell proliferation and
differentiation. Several TCDD endpoints are related to these processes, including early
eye opening, early incisor eruption, cleft palate, fatty liver, hyperkeratinization, and
cancer (Huff et aI., 1994; Matsumura, 1994). One interaction may be with the regulators
of the cell cycle itself, since treatment with TCDD results in the upregulation or
phosphorylation (activation) of cyclin dependent kinases (Devito et al., 1994; Ma &
Babish, 1993). This activation may be direct, or via the Mitogen Activated Protein
(MAP) Kinase pathway. The MAP kinase pathway transduces signals from plasma
receptors via protein phosphorylation events that ultimately induce transcription of the
"immediate early gene" c-Fos and activate c-Jun, two components of AP-l, a
transcription factor that regulates cell proliferation and differentiation via an unknown
mechanism. TCDD and Epithelial Growth Factor (EGF) cause similar increases in
phosphorylation activity and downregulation of EGF receptor, suggesting that TCDD
acts directly or indirectly on the EGF receptor (Kawamoto et al., 1989). Some have
hypothesized that the activation of the MAP kinase pathway begins with c-Src (an
associate of cytosolic AHR), followed by activation and downregulation of the plasma
receptors (Enan & Matsumura, 1996). On the other hand, the interaction may be more
direct. Early immunoprecipitation evidence suggests a direct interaction with TCDD
activated AhR with MAPK, one of the kinases in the MAP pathway (Ma & Whitlock,
1997). If the association between AHR and EGF signalling is proven, it is a mechanism
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that could explain a wide variety of HAR toxic effects that might occur independently of
DRE binding.
Immunosuppression. The AHR is required for certain TCDD-induced
immunotoxic endpoints. On the level of gross pathology, one of the most sensitive
endpoints of TCDD is the substantial loss of leukocytes and overall organ mass, causing
the condition termed thymic or splenic involution. Importantly, these effects are
completely abolished in AHR knockout mice, unequivocally implicating the AHR in
these effects (Fernandez-Salguero et aI., 1996). Studies using radiation chimeras with
AHR knockout mice has clarified that the most sensitive targets for TCDD toxicity are in
fact the hematopoetic elements rather than the supporting tissues (Staples et ai., 1998;
Thurmond et ai., 1999; Thurmond et ai., 2000). Despite the fact that it is now known that
hematopoetic cells in general are targets for PRAH toxicity, it is also of interest to
consider which branches of immunity are affected, and which measurable endpoints
might allow us to find clues among feral populations of marine mammals.
The most sensitive and classic assay used to test humoral (antibody) response is
the hemolytic plaque assay, which depends on the ability of the mouse to secrete
antibodies against sheep red blood cells (SRBC). It was noted early that mice with a high
affinity AHR (strain C57BL/6) were much more sensitive to humoral suppression by
3,3' ,4,4' TCB than mice possessing low affinity AHR (DBN2) (Silkworth & Grabstein,
1982). The severity of the suppressive effect correlated with the specific binding affinity
of the HAR to the ARR, supporting an AHR mediated mechanism. Such a relationship
has been shown for various PCB congeners (Davis & Safe, 1990) and polychlorinated
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dibenzofurans (Davis & Safe, 1988; Dickerson et al., 1990). That the AHR antagonist
alpha-napthoflavone can abrogate both CYPIA enzyme activity and suppression of
hemolytic plaques formed is consistent with an AHR-mediated mechanism (Blank et al.,
1987).
HAH may suppress the humoral response by interrupting the differentiation of
proliferating B cells to antibody-secreting plasma cells. In order to dissect the potential
targets of TCDD, Tucker et al. modified the hemolytic plaque forming assay to include
mitogen stimulation of spleen cells before exposing B cells to SRBCs and complement
(Tucker et al., 1986). Doubling TCDD dose did not modify the number of proliferating
cells or enzyme activity associated with proliferation of leukemia cells, but did lower by
half the number of plaques formed, thus showing that the differentiation step was affected.
Further, of B cells incubated with TCDD and B cell mitogens, 50% fewer displayed
plasma cell-specific (PC2) surface markers relative to control stimulated cells (Luster et
al., 1992). Since tyrosine phosphorylation is important in normal differentiation of B
lymphocytes, these authors also suggest and show partial evidence that disturbance of
required tyrosine phosphorylation signals by TCDD may be the mechanism of toxicity
(Clark et aI., 1991).
Cell-mediated immunity is also a target of AHR-mediated suppression. Kerkvliet
et al. showed that TCDD and hexachlorobiphenyls suppressed the tumor cell lysis activity
of cytotoxic T cells to the extent predicted by their AhR binding affinities (Kerkvliet et
al., 1990). AHR is present in both resting and activated T cells, but electromobility shift
assays show that the AHR complex binds DNA only in activated, TCDD treated cells
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(Lawrence et al., 1996). Serum corticosterone levels also increased in a HAR structure
dependent manner, but this response was later shown not to be part of the mechanism of
suppression (Dekrey & Kerkvliet, 1995). Further, TCDD does not appear to act via
interruption of cyc100xygenase or prostaglandin, despite the presence of DRE in the
promoters of cyc100xygenase genes and the immunoregulatory role of some
prostaglandins (Lawrence & Kerkv1iet, 1997).
Possible molecular mechanisms for AHR-dependent immunosuppression. Recent
studies have elucidated possible molecular roles of the AHR in immunosuppression and
may further help define targets for HAR (immuno)toxicity. For example, cytokines are
small proteins that play critical roles in immune cell-cell signaling during proliferation
and differentiation. Several cytokines have DREs in their promoters (Lai et al., 1996),
which suggests a direct mechanism for the AHR in the altered cytokine expression
patterns observed after TCDD treatment (Lai et al., 1997). One of the many functions of
cytokines is the timely induction of NF-kB, a transcription factor important in many cell
types and signaling pathways (Ghosh et al., 1998). It was shown recently that the AHR
can interact directly with re1A, a subunit of NF-kB (Tian et al., 1999). Since one of the
roles of NFkB is to inhibit apoptosis (Ghosh et al., 1998), occupation of NFkB with AHR
may be a way that AHR activation may cause lymphoid tissue involution. Apoptosis is
also observed in bone marrow pre-B cells upon treatment of dimethylbenzanthrazene
(DMBA, a non-halogenated AHR ligand). This endpoint appears to be AHR and
CYF1B1-dependent (Reidel et al., 1999; Mann et al., 1999).
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Evidence for AHR signal transduction in cetaceans
Consistent with its widespread occurrence in many terrestrial vertebrates, the
CYPIA also occurs in cetaceans. Several laboratories have demonstrated both CYPIA
activity and immunodetectable protein in microsomal fractions of various tissues
(Watanabe et al., 1989; White et al., 1994; White et al., 2000). Further, a correlation
between hepatic CYFIA content and blubber PCB concentrations suggests that this
enzyme is inducible (White et al., 1994; White et al., 2000). The likely involvement of
the AHR in this inducible response was supported when a putative beluga AHR was
detected by photoaffinity labeling of beluga hepatic cytosol (Hahn et al., 1994). The
detected protein had an apparent size similar to other mammalian forms of AHR. Using
sucrose-gradient centrifugation of cultured bottlenose dolphin kidney cells, Carvan et al.
also showed specific binding of a protein with a sedimentation coefficient expected for
AHR (Carvan III et al., 1995). These results are strong, though not definitive evidence for
the existence of a cetacean AhR.
Rationale and approach for thesis research
It is well documented that HAH accumulate in high quantities in the blubber of
cetaceans, but the effects of these high levels of exposure are unknown. Toxic responses
to the HAH in terrestrial mammals are mediated by the interaction of certain HAH with
the AHR, a cytoplasmic, ligand-activated transcription factor. The goal of these studies
was to ascertain the potential for HAH effects in cetaceans by characterizing the AHR
from the beluga, Delphinapterus leucas.
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A fundamental problem with cetacean research is the inability to conduct
controlled laboratory studies on live specimens. Moral and logistical factors prevent the
invasive studies required to directly determine the sensitivity of cetaceans to HAHs and
other compounds that act via the AHR. Because cetaceans are protected, sampling is
opportunistic and tissue quality is often poor. Expressing the protein in vitro would
alleviate the constant need for tissue from which to isolate the AHR, and allow molecular
studies of AHR function. Chapter 2 describes the cloning and sequencing of a beluga
AHR cDNA, and the generation of an expression vector for the in vitro expression of the
belugaAHR.
AHR-mediated effects involve many proteins, and differences in vulnerability
between species and strains within a species can be related to genetic variation at any
stage of the AHR signal transduction pathway. In some animal models, these differences
are known to be caused by allelic variation of the AHR itself. The molecular
characterization of the cetacean AHR is a first step in determining how well the mode of
AHR action in cetaceans is modeled by studies using laboratory rodents. Thus, in
Chapter 2, the TCDD binding affinity of the beluga AHR was compared with the affinity
of a mouse AHR (a relatively high affinity AHR), as well as that of a human AHR (a
relatively low affinity allele).
Relative potencies (REPs) and toxic equivalency factors (TEFs), for AHR agonists
are fractions that reflect the potential for an AHR agonist to elicit a TCDD-like response.
TEFs are used by regulatory agencies for risk assessment of mixtures of compounds. The
danger in using relative potencies to assess risk to marine mammals is that no relative
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potencies have been generated for or confirmed in any marine mammal species. Because
contaminant-related health effects on wildlife are important conservation issues for
endangered and protected stocks, there is a need for cetacean-based relative potencies for
scientific and management purposes. In Chapter 3, inhibition of TCDD binding to the
AHR by various structure classes of HAH is measured and relative potencies for beluga
and mouse AHR binding are derived.
Finally, because the AHR is necessary for the toxic effects of HAH, the relative
expression of the AHR among tissues and organs may help predict tissue targets for HAH
toxicity. Chapter 4 details the tissue-specific expression of AHR among various tissues
of belugas from the Alaskan Arctic.
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Figure 1. Structures of halogeuated aromatic hydrocarbons. Examples of a
chlorinated dibenzo-p-dioxin, a chlorinated dibenzofnran, and a polychlorinated
biphenyl are shown with the number of congeners indicated. Numbering and ortho,
meta, and para positions are shown on a PCB.
30
Canada
USA
Figure 2. World beluga distribution. The black area indicates the worldwide range
of beluga. Black dots are extralimital regions. The dashed shaded square indicates
St. Lawrence estuary, a highly contaminated region that is the habitat of a small
isolated population of beluga. The dashed and shaded circle indicates the Alaska
origin of the beluga samples used in these studies. Beluga from the Chukchi Sea
stock were harvested in Barrow or Point Lay, on the North Slope of Alaska. Map
modified from the St. Lawrence Beluga Recovery Team (St. Lawrence Beluga
Recovery Plan, 1995).
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Figure 3. Malignant tumors in St. Lawrence belugas 1982-1998. Reports of
malignant tumors occurring in St. Lawrence beluga were compiled from the St.
Lawrence Recovery Team (1995) and Lair et al. (1998).
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Figure 4. Functional domains of the mouse AHR. Regions critical for various
AHR functions were determined by deletion analysis using the mouse AHR. From
Fukunaga et al., (1995).
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Figure S. AHR signal transduction pathway and CYPIA induction.
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Chapter 2:
Molecular cloning and functional characterization of an
aryl hydrocarbon receptor in the beluga
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INTRODUCTION
Persistent organic pollutants (POP) are ubiquitous in the marine environment.
Sources of POPs include the use of pesticides (e.g. DDT), the breakdown of discarded
electronics and heavy machinery (PCBs), and the incineration of waste (PCDDs). POPs
are generally hydrophobic and resistant to metabolic and chemical degradation, and thus
tend to partition to lipid-rich sediments, cellular compartments, and tissues. POPs that
are not easily metabolized at low trophic levels bioaccumulate at higher trophic levels.
This is particularly evident in top feeding marine mammals such as odontocete cetaceans,
or toothed whales.
High levels of POP contamination have been documented in the beluga whale
(Delphinapterus leucas, family Delphinidae). The beluga whales of the St. Lawrence
have among the highest body burdens of PCBs ever documented in wildlife, which has
raised concern about the potential health impacts. PCB concentrations as high as 500
fig/g', 50-fold higher than what was observed as sufficient to cause reproductive and
hormonal dysfunction in terrestrial mammals, have been observed in beluga blubber
(Beland et al., 1993; Martineau et aI., 1987; Muir, 1990). Efficient transfer of maternal
POP burdens via lactation suggests that exposure to these environmental contaminants
may be highest during fetal and neonatal development of cetaceans (Cockcroft et aI.,
1989; Tanabe et al., 1988). High body burdens of POPs have long been suspected to play
a direct role in the observed cancer and reduced rate of reproduction with the St.
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Lawrence beluga stock (Bailey & Singer, 1995). However, very little is known about the
effects of POPs in cetaceans and other marine animals.
A subset of the POPs are the planar halogenated aromatic hydrocarbons (PHAH)
which include 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the planar representatives
of the polychlorinated biphenyls (PCBs). PHAH cause a number of effects in laboratory
rodents, including immunosuppression, endocrine dysfunction, enzyme induction,
carcinogenesis, and reproductive/developmental toxicity (Schmidt & Bradfield, 1996).
PHAH toxicity occurs after direct binding to the aryl hydrocarbon receptor (AHR), a
member of the bHLH-PAS family of transcription factors. Though many aspects of AHR
signaling have been described, most notably the induction of the CYP1A gene (CYP1Al
in mammals), the mechanism(s) of toxicity are not well understood. However, the lack
of toxic effects upon TCDD treatment of AHR knockout mice (Ah-/Ah-) confirms that the
AHR is necessary for TCDD toxicity (Fernandez-Salguero et al., 1996).
Beyond the mere presence or absence of the AHR, properties of the AHR also
determine sensitivity to PHAH and other AHR ligands. The experimental system that led
to the discovery and characterization of the AHR involved strains of mice that differed
greatly in their sensitivity to planar aromatic hydrocarbons, and as such were labeled
"Ah-responsive" (strain C57BL/6, Ahb alleles) and "Ah-non-responsive" (strain DBA/2,
Ahd allele). Sequencing the AHR alleles revealed that the difference between the Ahb-l
and Ahd alleles is a point mutation that causes one amino acid change (A375--. V375) in the
ligand binding region of the Ahd allele. Measurement of the binding affinities of the
alleles in vitro revealed that the effect of that mutation was diminished ligand binding
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affiinity in the Ah' allele from the more resistant strain (Poland et ai., 1994). Strain-
specific differences in TCDD sensitivity in the rat may also be AHR-dependent. In a
TCDD-resistant rat, a point mutation that does not affect ligand binding truncates the
protein and may compromise its transactivation function (Pohjanvirta et ai., 1998). In a
comparison of several bird species, relative binding affinities of AHRs match the relative
CYP1A inducibility and relative sensitivities to TCDD toxicity as assessed by an embryo
assay (Sanderson & Bellward, 1995). In humans it has recently been shown that an AHR
polymorphism (and not a CYP1A1 polymorphism) is associated with higher relative
CYP1A1 enzyme activity and protein in 3-methylcholanthrene-treated peripheral blood
lymphocytes (Smart & Daly, 2000). Taken together, this evidence suggests that
confirming the presence of the AHR and characterizing the AHR are potentially
important for evaluating PHAH sensitivity in any species.
Several laboratories have provided evidence for a functional AHR signal
transduction pathway in cetaceans. Profiles of PCBs and PCB metabolites measured in
cetacean blubber and in vitro measurement of hepatic microsomal enzyme activities are
indicative of CYP1A activity (Tanabe et ai., 1988; Watanabe et ai., 1989). Microsomal
activity indicative of CYP1A activity was first demonstrated in the minke whale
(Baiaenoptera acutorostrata) (Goksillyr et ai., 1986). CYP1A expression in cetaceans
was later confirmed by the direct measurement of CYP1A protein in the minke whale
(Goksillyr et ai., 1988), and beluga (White et ai., 1994). The presence of a cetacean AHR
that is capable of specific TCDD binding was confirmed using lysates from a dolphin
kidney cell line (Carvan III et ai., 1995) and beluga liver cytosol (Hahn et ai., 1994).
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To further assess the potential susceptibility of cetaceans to PHAH, we are
characterizing the AHR of the beluga. In this report, we describe the cloning, in vitro
expression, and initial functional analysis of a beluga AHR. We compare this beluga
protein with a relatively high affinity AHR, the product of the mouse Ahb-1 allele (Poland
et al., 1994), and a human AHR (Dolwick et al., 1993). These studies focus on the
beluga for several reasons: 1) the population in the St. Lawrence Estuary, Canada has
long been suspected to be negatively affected by PHAH exposure; 2) distributions of
stocks span a gradient of environmental contamination (Muir, 1990); 3) access to a
captive population has allowed baseline health parameters to be determined; and 4) it has
recently been proposed as a "model cetacean species" by a working group of marine
mammal toxicologists convened by the Marine Mammal Commission (MMC, 1999).
This is the first molecular characterization of an AHR in a marine mammal. We suggest
that this is a promising approach for gathering species-specific data relevant to
contaminant sensitivity when in vivo dosing experiments are ethically, legally, and
logistically impossible.
MATERIALS AND METHODS
Materials
The mouse AHR plasmid (pSPORTmAHR) containing the Ahb-1 allele and human
HepG2 AHR (pSPORThAHR2) expression vectors were graciously provided by Dr. C.
Bradfield (McArdle Center for Cancer Research, Madison WI)(Burbach et al., 1992;
Dolwick et iii., 1993). 2,3,7,8-Tetrachloro[1,6-3Hjdibenzo-p-dioxin (33 Ci/mmol) was
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obtained from Chemsyn Science Laboratories (Lenexa, KS) and purified to ~95%
radiochemical purity by high performance liquid chromatography (Gasiewicz & Neal,
1979). 2,3,7,8-Tetrachlorodibenzofuran (TCDF) was obtained from Ultra Scientific
(Hope, RI). Methylated [methyp4C)ovalbumin was obtained from NEN Life Science
Products, Inc. (Boston, MA). Methylated [methyl-14C)catalase was synthesized as
described (Dottavio-Martin & Ravel, 1978). The C57BLl6 mouse was provided by Dr.
D. S. Sherr (Boston University School of Public Health, Boston, MA).
Tissue collection
Beluga liver was collected from Mackenzie Delta, NWT, Canada as described in
White et al. (1994). Liver tissue was also collected from a subsistence hunt of Chukchi
Sea beluga in Alaska during the summer of 1997. Liver tissue was snap frozen in liquid
nitrogen approximately 3-4 hours after death. Tissues were maintained at liquid nitrogen
temperatures throughout transport, storage, and powdering with mortar and pestle. The
C57BLl6J mouse was killed by cervical dislocation and the liver was extracted from the
animal and snap frozen minutes after death.
RNA isolation
Total RNA was isolated from liver tissue using the guanidinium isothiocyanate
method (Clemens, 1984). Messenger RNA was isolated using oligo dT columns
(Collaborative Research, Bedford MA) (Maniatis et al., 1982). The quality of the total
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and messenger RNA was confirmed by visualization on ethidium bromide-stained
agarose minigels and quantity was determined by UV absorbance.
Oligonucleotide primers:
Primers were synthesized by National Biosciences, Life Technologies, or
Integrated DNA Technologies. Degenerate primer sequences were: AHR-A1, AHR-A2,
AHR-B1, AHRB2 (Hahn and Karchner, 1995). Gene-specific primers were: Dlb538: 5'-
TIC CTITGG CAT CAC AAC CAGTAG-3'; Dlb467: 5'-CGG ATITCA AGT ATG
GAT GGT GG -3'; Dlfl52: 5'- GGG CGT TAA ATC CTI CAC AGT GTC C-3';
Dlf258: 5'- GAA CTC TIC GTC TAT GGA AAG GTG C-3'; Dlf467: 5'-CCA CCA
TCC ATA CTI GAA ATC CG-3', Dlf538: 5'-CCT ACT GGTTGT GAT GCC AAA
GGA A-3', DlExon9F: 5' -TGC AGT CGA ATG CAC GCT TAG-3'; DIUTRrev: 5'-
AAC CAA GAT GAA AAA TGG GCT TG-3'; 5nat-hind3: 5'-CCC AAG CTI GGG
CAC CAT GAA CAG CAG C-3'; 5koz-hind3: 5' -CCC AAG CTI GGG CAC CAT
GGA CAG CAG C -3'; xba1-utr: 5'-GCT CTA GAG CAA CCA AGA TGA AAA ATG
GGCTIG-3'.
Cloning and Sequencing ofbeluga AHR eDNA
RTIPCR
Messenger RNA isolated from a beluga that stranded in the Mackenzie River
Delta, Canada was made into cDNA using random hexamers. Degenerate primers AHR-
A2 and AHR-B2 containing inosines were used to amplify an internal beluga AHR
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fragment from the cDNA with the following PCR conditions: 94° /5:00; (95/:15,45°/:30,
72°/1:00) for 45 cycles followed by a 7 minute final extension. The same primers were
used in direct sequencing of the amplified fragment in both directions using the
Sequenase Version 2 Kit (US Biochemical) with modifications for direct sequencing as
described by Bachmann et aI., (1990). Sequencing revealed 480 bp that shared high
sequence identity with mammalian AHRs based on a BLAST search. Subsequent efforts
to obtain a full-length clone using RACE techniques were unsuccessful. Suspecting that
sample quality may have been compromised, we turned our efforts to beluga samples
obtained in 1997 from Alaska.
Poly A+ mRNA isolated from a beluga collected in 1997 in Alaska was used with
a GeneAmp RTIPCR kit (Roche, Blanchberg, NJ) with the following conditions in the
Perkin Elmer 2400 thermocycler: 94° /5:00; (95°/:15, 60°/:30, 72°/1:00) for 35 cycles.
Degenerate primers AHR-A1 and AHR-B1 containing inosines amplified a 648 base pair
fragment that was sequenced with a Licor4000 automated sequencing system using Excel
II cycle sequencing kit. The sequence matched the 480 bp fragment that was sequenced
previously.
Gene-specific primers were then designed for 5' and 3' RACE. The 5' gene-
specific primers Dlb538 and Dlb467 and the 3' gene-specific primers Dlfl52, Dlf258,
Dlf467, Dlf538 were used with the Marathon gene amplification kit (Clontech, Palo Alto,
CA). "Touchdown" PCR was used for all RACE reactions: 94°/ :30; (94°/:05,72°2:00)
(5 cycles), (94°/:05,70°12:00) (5 cycles), (94°/:05, 68°2:00) (25 cycles). Nested 5' RACE
was carried out on the b538 product using Dlb467. All four of the 3' RACE reactions
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yielded a product of approximately 2 kb. The Dlf258 and Dlf538 primer products were
sequenced, and both were AHR. The 3' fragment was too large to obtain a complete
sequence, so two more primers were designed internal to F538 and the adapter primer
and "primer walked" with DLExon9F and DlUTRlrev with conditions 95°/5:00;
95°/:30,56°/30,72°/:30 (35 cycles); 72°17:00 extension in order to obtain the entire
sequence of the 3' RACE clone. All sequencing was done on the Licor4000 automated
sequencing system using Excel II cycle sequencing kit.
Once sequencing revealed the start and stop codons of the coding region, primers
were designed to amplify the full-length eDNA. Two 5' primers were designed, one with
the native sequence (5nat-hind3) and the other with a Kozak sequence (5koz-hind3) (A-
>G switch at +4) (Kozak, 1987). Both contained HindlII restriction sites outside of the
coding region. The full length beluga AHR was amplified using Klentaq (a mixture of taq
polymerase and proofreading polymerase) of the Advantage cDNA PCR kit (Clontech,
Palo Alto, CA). Primer pairs 5nat-hind3/ xbal-utr and 5koz-hind3-/xbal-utr were used in
touchdown PCR: 94°/ 1:00; 94°/:05, 70°2:00 (5 cycles); 94°/:05,68°/2:00 (5 cycles);
94°/:05,66°2:00 (25 cycles); 68°17:00.
Expression vector construction
The the full-length AHR products derived from primer pairs 5nat-hind3/xbal-utr
and 5koz-hind3-/xbal-utr were cut with HindlII and Xbal (Promega, Madison, WI) and
cloned into HindlII and Xbal sites of pcDNA3.0 (Invitrogen) and pSP64 Poly(A) vector
(Promega, Madison WI). This generated a native and a Kozak 5' end under both the T7
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(pcDNAbelAHRnat and pcDNAbelAHRkoz) and SP6 (pSP64belAHRnat and
pSP64beIAHRkoz) promoters. Minipreps of all constructs were digested with HindIII,
Xba, Pstl and BamHl. Preps that contained expected digest patterns were observed for
pcDNAbelAHRnat, pSP64belAHRnat, and pcDNAbelAHRkoz, so these constructs were
tested for expression efficiency. The constructs were cleaned and purified using the
Qiafilter Maxi Plasmid Purification kit (Qiagen, Santa Clarita, CA). Proteins were
synthesized using the TNT Quick Coupled Transcription and Translation system
(promega) for T7 or SP6 promoters in the presence of [35SJ-methionine. The
pSP64belAHRnat construct under the SP6 promoter expressed 2-3 fold higher levels of
protein compared to the pcDNA constructs, and the native belAHR sequence was
expressed at levels similar to the SP6 positive control. To ensure that the
pSP64belAHRnat expression plasmid (hereafter referred to as pSP64beIAHR) was free of
PCR errors, the vector was digested with HindIIIlBamH1, Pstl/Sacl, and Cla1IXba and
subcloned into pBluescript into the same sites. Each subclone was completely sequenced
and was confirmed to match the belAHR consensus sequence.
Cytosol preparation
Liver cytosol was prepared as described in Hahn et al. (1994). Cryo-preserved
liver was first powdered while under liquid nitrogen, then homogenized in MEEDGM
(35mM MOPS, 1mM EDTA, 5 mM EGTA, 0.02% NaN" 20mM Na2Mo04 , 10% (v:v)
glycerol, 1mM DTT, pH 7.5 containing protease inhibitors and PMSF). After serial
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centrifugations of 750g, 12,000g, and 100,000g, the supernatants were frozen in liquid
nitrogen until analysis.
In vitro protein synthesis
Beluga, mouse and human AHR proteins were synthesized using the TNT Quick
coupled Reticulocyte Lysate Systems (Promega) in the presence or absence of 35S
labeled methionine. Size of the proteins was confirmed by SDS-PAGE with 5fll of
reaction containing 35S-labeled AHR, followed by fluorography and autoradiography.
Western blotting
2 fll of mouse, human, and beluga TNT reaction, and 100flg beluga liver cytosol
were loaded onto a tris-acetate gel (Novex). The gel was blotted onto 0.22 flID PVDF
membrane, and probed with SA-21O rabbit anti-mouse AHR polyclonal antibody
(Biomol) and secondary goat anti-rabbit antibody (Schleicher & Schuell). Bands were
visualized with CSPD chemiluminescent substrate (Tropix).
Velocity sedimentation
The beluga, mouse, and human AHR constructs and the empty pSP64polyA
vector were used in in vitro transcription and translation reactions and the resulting
proteins were analyzed by velocity sedimentation on sucrose gradients in a vertical tube
rotor (Tsui & Okey, 1981). For each AHR, two identical TNT reactions (l00 fll total)
were combined, diluted 1:2 with MEEDMG buffer (25 mM MOPS, pH 7.5 @ 20°C,
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containing 1 mM dithiothreitol, I mM EDTA, 5 mM EGTA, 0.02% NaN" 20 mM
Na2Mo04, 10% (v:v) glycerol plus a mixture of protease inhibitors: aprotinin (100
units/ml), pepstatin A (7llg/ml), TLCK (20 !1M), leupeptin (5 Ilg/Il!) (Hahn et al., 1994).
Each sample was split into two 150-1l! aliquots and incubated with ['H]TCDD (2 nM) ±
TCDF (400 nM) for 8 hr at 4°C in glass tubes. Following incubation, the in vitro
expressed proteins were treated with dextran-coated charcoal (DCC) (charcoal:dextran
10:1 w:w). In a polypropylene tube, !lOll! of the incubation were mixed 1:1 with
7mg/ml DCC in MEEDMG buffer, followed by vortexing and centrifugation. Cytosols
were diluted in MEEDMG buffer to 5 mg/ml and incubated under the same conditions as
the expressed proteins, except that they were not treated with DCC. The ['H]TCDD
concentration was verified by sampling each tube for total counts. 2001l! of the TNT
incubation and 230111 of cytosol incubations were applied to 10-30% sucrose gradients
that were prepared in MEEDMG buffer (Coombs & Watts, 1985). The gradients were
spun for 140 min at 60,000 rpm at 4°C in a VTi 65.2 rotor, after which 150 Il! fractions
were counted using a Beckman LS5000TD Scintillation counter. Specific binding is
defined as the difference between total binding (incubations containing ['H]TCDD) and
nonspecific binding (incubations containing ['H]TCDD plus a 200-fold excess of TCDF).
C4C)-Ovalbumin (3.6 S) and [14C)-catalase (11.3 S) were added as internal sedimentation
markers; they eluted in fractions -5-6 and -18-19, respectively. Sedimentation
coefficients of AHR proteins were also determined (Martin & Ames, 1961).
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Saturation binding
The saturation binding assay with in vitro expressed AHRs is a modification of
the binding assay of ['HlTCDD to hepatic cytosol (Poland & Glover, 1976). A major
difference in the assay used here is the use of unprogrammed TNT lysate to determine
non-specific binding. In tissue preparations as described above, specific binding is
determined from the difference between total ['HjTCDD binding by cytosol and the
[3HjTCDD binding measured when excess cold ligand is used to block specific binding
sites. With in vitro expressed proteins, the specific binding sites are synthesized.
Therefore, the lysate provides a convenient means for measuring non-specific binding
without the need for duplicate tubes for each species tested. The beluga, mouse, and
human AHR constructs were synthesized by in vitro transcription and translation as for
the velocity sedimentation assay. The reactions were then diluted 1:8 in MEEDGM with
protease inhibitors. Diluted TNT -expressed proteins were incubated in a 16xlOO mm
glass tube for 7-8 hours with one of nine concentrations (0-8nM nominal) of ['HjTCDD
in DMSO. 20f.ll aliquots in duplicate were taken at the beginning of the incubation to
measure the actual concentrations of [3HjTCDD in each tube. After the incubation, 30fll
were transferred in triplicate aliquots to standard 1.5 ml polypropylene tubes containing
30 f.ll of 2.3 mg DCC/ml MEEDGM. Tubes were vortexed for 5 seconds 3 times, with a
5 minute incubation on ice between each vortexing. Tubes were then spun at 7000g for 3
min. 40fll of the supernatant was counted to measure bound [3HjTCDD. Total counts and
total binding were measured on a Beckman 5000 scintillation counter.
47
All curves were plotted as "free" ['HlTCDD (nM) vs. bound ['H]TCDD (DPM).
Bound TCDD was determined directly from measured DPM. Free ['H]TCDD was
determined by subtracting the bound DPM from the total counts for each tube, and
converting this difference to nM. The unprogrammed lysate data (non-specific binding)
was fit to a linear model, and the slope was used to calculate the non-specific binding that
corresponded to total binding at each concentration of free TCDD. The difference
between the actual total binding and the calculated non-specific binding was the specific
binding. The specific binding points were fit to the equation: B = Bm,,[L][L] + Kd
where B is
bound [3H]TCDD, Bm", is maximum bound receptor (DPM), L is concentration of free
ligand, and Kd is the dissociation constant. The Kd values from 3 experiments each for
beluga, mouse, and human AHRs were compared using unpaired Students t-test. Curve
fits and statistics were done with SigmaPlot 5.0 for the Macintosh (Jandel Scientific).
RESULTS
Beluga AHR cloning
A beluga AHR cDNA was isolated from liver of belugas collected from Canada
and Alaska (Figure 1). The initial attempts utilized a beluga that stranded in the
Mackenzie River Delta, Canada. This individual was among those for which PCB levels
were measured and CYP1A was successfully identified by immunoblotting (White et al.,
1994) and AHR was identified by photoaffinity labeling (Hahn et aI., 1994). Using
degenenerate primers designed based on previously published mammalian AHR
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sequences (Hahn & Karchner, 1995) we isolated the AHR-A2/AHR-B2 fragment after
using low stringency conditions (see Methods). Efforts to isolate the full-length beluga
AHR cDNA using the Mackenzie River Delta beluga sample were not successful, so
subsequent efforts utilized a beluga liver sample collected in Alaska in 1997. From
freshly prepared mRNA, a 648 bp AHR-Al/AHR-Bl fragment was isolated that
encompassed the AHR-A2/AHR-B2 fragment and matched its sequence exactly.
The remaining beluga AHR sequence was obtained with 5' and 3' RACE.
Together the RACE fragments and original PCR products spanned a 3.2 kb cDNA that
contained a 2535 bp open reading frame, 29 bp of 5'UTR, and 699 bp of3' UTR. No
poly A tail was detected, despite the fact that the cDNA was primed with oligo dT. This
might be explained by cleavage of the end of the 3'UTR before the kit adapters were
ligated to the cDNA ends, or by priming of the adapter primer API upstream of the poly
A tail. The consensus sequence was based on 44 sequences; 38 were obtained by cycle
sequencing of 21 separate clones and 6 sequences were from direct sequencing of PCR
products in forward and reverse directions. The ORF encoded an 845 amino acid protein
with predicted size 95.5 kDa. The minimum number of sequences that were used to form
a consensus at each base was 4 within the coding region, and 2 in the UTR (Figure 2).
The translated consensus sequence is shown in Figure 3.
The alignment with mouse AHR b-I allele (Burbach et al., 1992) and the human
AHR (Dolwick et aI., 1993) is shown in Figure 4. Among published mammalian AHR
sequences, the beluga AHR shares the highest (85%) overall amino acid sequence
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identity with the human AHR. The amino acid sequence identity of the beluga AHR
shared with the mouse AHR is 75%.
The AHR has functional regions whose boundaries have been elegantly
determined for the mouse AHR (Burbach et al., 1992; Dolwick et al., 1993; Fukunaga et
al., 1995; Poland et aI., 1994). In brief, the bHLH is involved in DNA binding, the PAS
domain is involved in ligand binding, dimerization with ARNT, and hsp90 binding, and
the C-terminus is believed to function mainly in transcriptional activation. When the
homologous regions of the beluga AHR were compared to mouse and human AHR
genes, the beluga AHR again shared the greatest sequence identity and similarity with the
human AHR (Figure 5). As in other bHLH/PAS proteins, the N-terminus is much more
highly conserved between species as compared to the C-terminus. Clusters of glutamine
residues appear among amino acids 598-775 of the beluga AHR, 20 in total (27%)(Figure
4). In the same region, mouse AHR is 28% glutamine, and human AHR is 29%
glutamine. This "Q-rich" domain, which has been shown to contribute to transcriptional
activation in other transcription factors, is suggested to have also have a role in
transcriptional activation in the AHR (Burbach et al., 1992).
Certain amino acid changes in the AHR confer dramatic changes in AHR
function. One of these is the amino acid 375 of the mouse AHR; an alanine at this
position in the Ahb-! allele confers about four to five-fold greater binding affinity
compared to the Ahd allele, where the residue is a valine (Ema et al., 1994; Poland et al.,
1994). Like the high affinity mouse allele, the beluga AHR has an alanine at the
analogous residue 380. Another notable mutation is found in AHR of Hepa~1 cells (D
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mutant strain) at residue 216 of the mouse Ahb.! allele, between the PAS-A and PAS-B
domains. A point mutation that changed this residue from cysteine to tryptophan
conferred a complete loss of DNA binding by the AHR-ARNT heterodimer (Sun et al.,
1997). As with the human AHR and the wild type mouse Ahb.! allele, the beluga AHR
has the conserved cysteine at analogous residue 221 (222 in human AHR).
Characterization ofbeluga AHR synthesized in vitro
The beluga AHR protein was expressed in a rabbit reticulocyte lysate system
under control of the SP6 and T7 promoters, with and without modification to create
Kozak sequences near the start codon. An autoradiogram of a polyacrylamide gel
containing the proteins made with [35S]-methionine revealed that the native AHR
sequence under the SP6 promoter was the most efficiently expressed construct (Figure 6).
The apparent size was -110 kDa, 15% different from its predicted size of 95.5 kDa, but
consistent with its apparent size as observed by photoaffinity labeling (Hahn et al., 1994).
All functional assays of in vitro expressed protein were henceforth conducted using the
pSP64beiAHR plasmid.
The fluorogram in Figure 7a shows the expressed beluga, human, and mouse
proteins synthesized in the presence of [35S]. The relative sizes are consistent with the
relative sizes of their predicted molecular weights of 95.5,90.6, and 96.0 kDa for
pSP64beIAHR, pSPORTmoAHR, and pSPORThuAHR products, respectively. Figure
7b is a Western blot probed with an anti-mouse AHR polyclonal antibody. This antibody
clearly recognizes the in vitro-expressed beluga AHR, along with the expressed mouse
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and human AHR expression products. The blot also shows a band in beluga liver cytosol
that was equivalent in size to the expressed beluga AHR. Likewise, the size of the band
detected in mouse liver cytosol was the same as the expressed mouse AHR.
We next determined the ability of the in vitro -expressed beluga AHR to bind
['H1TCDD. The beluga, mouse, and human AHR TNT products all showed a clear peak
of binding that was eliminated upon incubation with 200-fold excess TCDF, which
indicated that the ['H1TCDD binding was specific. The concentrations and sedimentation
coefficients of AHR from representative experiments are shown in Figure 8. The
expressed beluga and human AHR sedimented with a peak at 10.5 S, and the mouse AHR
peak was at 10 S. The mouse TNT reaction produces the highest concentration of
binding AHR (111 fmol AHR/50 III reaction), followed by beluga (69 fmol/reaction) and
human (24 fmol/reaction). No specific binding was observed with the unprogrammed
lysate, confirming that all detectable specific binding was from the expression products
alone, and not from lysate proteins.
The peaks of specific binding in mouse and beluga cytosol were centered at 9.5 S.
In contrast with the high levels of binding observed for TNT expressed AHRs, specific
binding in C57BL/6 mouse liver cytosol was 24 fmol AHR/mg cytosol protein, and that
in beluga liver cytosol was 7 fmol/mg. When the beluga liver cytosol was treated with as
little as 0.025-2 mg DCC/mg protein to adsorb free ['Hl-TCDD, a significant amount of
specific binding was lost (not shown). Sensitivity of cytosolic AHR to charcoal treatment
has also been observed in human tissues (Manchester et al., 1987) and in fish cells
(Lorenzen & Okey, 1990). We did not observe this sensitivity to charcoal with TNT-
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expressed proteins. Overall, these results show that beluga AHR binds [3Hl-TCDD in a
highly specific manner, and that in vitro expression is a suitable way to generate large
amounts of AHR protein without the need to collect and process large amounts of
difficult to obtain tissue.
Relative binding affinities ofbeluga, mouse, and human AHRs
Having established the ability of the beluga AHR to specifically bind ['Hl-TCDD,
we next sought to compare the TCDD binding affinity (~) of the in vitro expressed
beluga AHR with Kds of expressed mouse and human AHRs. The saturation binding
assay with in vitro expressed AHRs is a modification of the cytosolic binding assay
described by Poland et aI. (Poland et al., 1976). Critical to these experiments is the
achievement of an abundance of "free" ligand relative to bound ligand so that the [3Hl-
TCDD concentrations used to measure the dissociation constant are not overly distorted
by associations with lower affinity binding sites. A satisfactory balance of detectable
specific binding (~ 500 disintegrations per minute) and fraction of "free" ['Hl-TCDD (~
80) for the beluga AHR was determined to be around a lO-fold dilution of the lysate
(Figure 9). A 9-fold dilution was used for all subsequent Kddeterminations.
Bound ['Hl-TCDD was separated from "free" ['Hl-TCDD with the use of
dextran-coated charcoal, and the mean of 3 replicates per concentration of ['H1TCDD
was plotted as total bound ['H]TCDD. As shown in Figure 8 (panel F), unprogrammed
lysate (UPL) does not bind ['Hl-TCDD specifically, so UPL was used to determine the
amount of rii:m-specific binding. This eliminated the need for a second set of tubes that
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are incubated in parallel with ['Hl-TCDD, plus excess unlabeled competitor. Binding to
UPL increased linearly with increasing amount of ['Hl-TCDD in the concentration range
used, consistent with the theoretical notion that non-specific binding sites are high
capacity and not saturable. Specific binding was then calculated as the difference
between the total binding points and the linear non-specific binding curve. Specific
binding was fit to the Langmuir binding isotherm to determine the binding affinity Kd and
the theoretical maximum binding (Bm,,). A representative set of experiments is shown in
Figure 10, and data from 3 independent experiments is summarized in Table 1. The
beluga AHR exhibited high affinity for ['H]-TCDD that was not significantly different
from that of the mouse AHR, and both the beluga and mouse AHRs had binding affinities
that were significantly greater than that of the human AHR.
The curves in Figure 10 are plotted as Scatchard plots in Figure II. For the
human AHR, the Kd calculated using the Scatchard analysis was within I standard
deviation of the Kd predicted by the curve fit method, but the Kd for mouse (within 5 SD)
and beluga (within 2 SD) were not as close. The data transformation in the Scatchard
analysis causes two problems: I) it requires a correlation between X and Y values for
which X is dependent on Y, and 2) it"compresses" data at the high and low ends of the
curve (Kenakin, 1999). Both of these conditions exacerbates error at the ends of the data.
In this system, the low ['H1TCDD concentrations are subject to the highest error because
of scintillation counting limitations. The high ends of the curve are also difficult to
obtain because of the very low solubility of TCDD. Since curve-fitting does not depend
on transformed data, estimates obtained from direct curve fitting are more accurate.
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DISCUSSION
The objective of these studies is to assess the potential impact of a persistent and
toxic class of environmental contaminants, the PHAH, on the health of cetaceans. The
toxicity of PHAH has been clearly established in other mammalian species. For this
reason, PHAH, among other contaminants and factors related to environmental
degradation, have been implicated in apparent increases in marine mammal disease and
mortality. However, species-specific variability in sensitivity to PHAH confounds and
limits broad speculation on the toxicological significance of the high tissue burdens that
are observed in marine mammals.
One way of assessing whether effects by PHAH might be significant in a given
species is to examine proteins involved in the mechanism of toxicity. We chose to
examine the AHR, a protein known to interact directly with PHAH and play an important
role in PHAH toxicity. However, biochemical examination requires intact proteins from
high quality tissue samples, which are difficult to collect for marine mammals. We
cloned and expressed a beluga AHR in vitro, which circumvented the problems inherent
in both marine mammal tissue sampling (autolysis before tissues can be collected, rare
sampling opportunities) and working with AHR (low abundance, labile protein). The
results presented here show that PHAH are likely to cause effects via the AHR and thus
have the potential to affect cetacean health.
Beluga AHR shares high sequence identity with other mammalian AHRs
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Cloning and sequence analysis of a full-length cetacean AHR confirms and
extends earlier observations of a protein in cytosols from beluga liver and a dolphin cell
line that binds dioxin specifically (Carvan III et aI., 1995; Hahn et al., 1994). The beluga
AHR possesses major functional domains that are characteristic of AHRs, including the
bHLH, PAS A, PAS B, and glutamine-rich regions (Figure 4). Like other AHRs, the N-
terminus is highly conserved and the C-terminus is much less conserved, and might be
termed "hypervariable" as by others (Dolwick et al., 1993). Overall, the beluga AHR
sequence is most identical to human AHR (Dolwick et al., 1993). It differs by only 3
amino acids in total length of the coding region and shares 85% identity with human
AHR and 75% identity with the Ahb.! allele expressed in the C57BL/6 mouse strain and
wild-type Hepa-1c1c7 cell line (Burbach et al., 1992). Within the bHLH and PAS
domains (as defined by homology to the mouse AHR), this identity is much higher
(Figure 5).
Despite the high degree of sequence identity among mammalian AHRs, subtle
changes in the amino acid sequence can cause remarkable changes in AHR function. A
much greater understanding of the AHR structure-function relationship is required before
function may be deduced accurately from AHR sequence data. For this reason, we
characterized the in vitro binding affinity for the beluga AHR.
Beluga AHR is a high affinity AHR
In order to conduct a comparison of the beluga AHR with AHRs from terrestrial
mammals that have been reasonably well characterized, we chose a relatively "high
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affinity" and a relatively "low affinity" AHR to use alongside the beluga AHR in our
experimental system to determine TCDD binding affinities. The "high affinity" AHR
was the mouse AHR allele Ahb-1 (Burbach et al., 1992). In vitro, the Ahb- 1 protein has a
4-5 fold greater binding affinity than the mouse Ahdprotein (Bma et al., 1994; Poland et
a!., 1994). The representative "low affinity" AHR that we used was a human AHR that
was cloned from the hepatic carcinoma cell line Hep G2 (Dolwick et al., 1993). In vitro,
the Hep G2 AHR has a 4-5 fold lower affinity for TCDD than the mouse Ahb-1 allele,
comparable to the binding affinity of the Ahdallele (Bma et al., 1994).
Determination of the Kds of in vitro expressed beluga, mouse and human AHRs
by saturation binding showed that the beluga AHR is a high affinity AHR. In this
system, the belAHR has a Kdof -0.43 nM, the mouse Ahb-1 AHR has a Kdof 0.68, and
the human AHR has a Kdof -1.63 nM. Absolute binding affinities are highly dependent
on the protein concentrations used in the incubations, with apparent binding affinities
decreasing with increasing protein concentrations (Bradfield et al., 1988). Therefore, Kds
are best used to describe relative binding affinities that are determined under similar
experimental conditions and protein concentrations. Some experiments and within-lab
data sets within which Kos can be compared are compiled in Table 2. Despite the protein
concentration caveat, the relative binding affinities observed for the mouse and human
AHRs in my studies are in reasonable agreement with observations from other
laboratories, and in some cases, the relative and absolute Kds are in very close agreement
(see data from (Ema et al., 1994)).
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Two conclusions can be drawn from these data that are potentially important for
understanding the susceptibility of beluga to PHAH. First, the beluga AHR has a binding
affinity that is statistically no different than that of the mouse (Ahb- ' ) AHR. Second, the
beluga AHR has a ['H]-TCDD binding affinity that is -4-fold greater than the binding
affinity of the human AHR (Figure 9, Table 1). In the case of inbred mice, a single
alanine to valine switch at residue number 375 is responsible for a 4-5 fold difference in
the in vitro ligand binding affinities observed between the Ahb-
'
allele and the Ah' alleles
(Bma et al., 1994; Poland et al., 1994). At the homologous residues in the beluga and
human AHRs, the beluga AHR possesses an alanine (Ala380, similar to the Ahb-
'
allele),
while the human AHR has a valine (Val38 " similar to the Ahd allele). This alternate
residue might also contribute to the 4-fold difference in binding affinity between the
beluga and human AHRs observed here. In vivo studies using congenic mice, the
homozygous Ahb•' mouse strain shows 8-24 fold higher sensitivity to toxic effects
compared to the homozygous Ahd strain (Birnbaum et al., 1990). Thus, in the case of
mouse strains, the AHR binding affinity phenotype can predict the PHAH sensitivity
phenotype. If the same is true for the beluga AHR phenotype, then the beluga may be
particularly sensitive to PHAH.
Significance ofa high affinity AHR in cetaceans
Some diseases and pathologies are prevalent in cetacean populations that carry
high contaminant burdens in their tissues, suggesting a potential link between
contaminants and immunosuppression (Aguilar & Borrell, 1994; Borrell et al., 1996;
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Jepson et al., 1999). In particular, the contaminant-burdened St. Lawrence population of
beluga have exhibited susceptibility to mild pathogens, and have an high occurrence
(approaching rates in humans) of metastatic cancers (Beland et al., 1993; Martineau et
al., 1988). Among other possibilities, this may indicate a reduced capacity for cellular
and/or the innate immune response in this population (Deguise et al., 1995).
Establishing a cause and effect relationship between contaminant burdens in
marine mammals and disease is a difficult challenge. Because controlled dosing
experiments in cetaceans are impossible, others have suggested a "weight of evidence"
approach for addressing questions regarding contaminant effects in marine mammals
(Ross, 2000). Thus, the evidence in favor of a role of contaminants, and in particular the
PHAH, in cetacean disease is the following. I) Certain populations of cetaceans are
highly exposed to POPs, as evidenced by very high levels detected in blubber and tissues
(Kannan et al., 1993; Martineau et aI., 1987; Ross et al., 2000) 2) There is a correlation
between high POP burdens in cetaceans and death by disease (Aguilar & Borrell, 1994;
Jepson et al., 1999). 3) Suppression of both the humoral and cellular branches of the
immune system, as well as metastatic cancers such as those observed in cetaceans can be
induced by TCDD in laboratory rodents (Huff et al., 1994; Kerkvliet et aI., 1990;
Kerkvliet et al., 1990; Schwarz et al., 2000; Staples et aI., 1998).4) The observation of
CYPIA induction in belugas and the observed correlation with PCB levels suggests that
the AHR is activated by low levels of contaminants in feral cetaceans (White et al.,
1994).
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This study contributes further to the weight of evidence by showing the following.
5) Beluga possess an AHR that shares a high degree of sequence identity with other
mammalian AHRs. 6) Finally, the beluga AHR binds TCDD with an affinity that is at
least as high as a "high affinity" mouse AHR. The finding of a high affinity AHR in a
cetacean is consistent with a role for the AHR and PHAH in the toxic effects observed in
environmentally exposed cetaceans. Future work will focus on verifying this apparent
connection between toxicant exposure and toxic effect in other systems and with other
AHR agonists.
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Figure 1. Strategy for the PCR amplification and sequencing ofa beluga AHR
eDNA. The sequence of the full length cDNA was derived from an internal PCR
fragment isolated with degenerate primers, a 5' RACE product, and a 3' RACE
product, and a bridgiug internal PCR product isolated with specific primers. Sequence
was from each region was derived from a minimum of 2 minipreps and 2 independent
reactions. The 3.3 kb cDNA contained a 2535 bp open reading frame that encoded an
845 amino acid protein with a predicted size of 95.5 kDa.
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Figure 2. Sequence coverage of beluga AHR eDNA. A minimum of 4 sequences
were used to determine the consensus sequence of the beluga AHR open reading
frame, and at least 2 sequences were used to determine the consensus sequence of the
UTR. Almost all sequencing was done on the Licor 4000 automated sequencing
system (see text for details).
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K PYA Q II rIP C 5 Q S V L P P B B Jt 0 T Q L D r 718
2155 CCC AT'l' GOG GAT TTT !UA CCA GeC CCl\. TAC CCT 1oC.A ACT TeT TC'I' AAT TTA !UA GAl: TTT QTe 1>CA TOT TTA CAA GTT
PIG D rEP A P Y P T 'l' S S 5 L I: D i' V T C L Q V 144
2233 CCT Cll.A AGe CAA N>G CAe IolGA CTC AAT CCA CAG '1'CA Gee AT,. O'l'A ACT CCT CAG ACG 'li'GT TN:; At;T GOO GCT GN 'l'ClI.
P Q S Q II; B G L III P Q S A X V T P Q T C Y T G A V S 770
2311 A'l'O TAe CAG Ne CAG CCG GAA GCT CAG CAC AGe CAT G'M acT CAG ATG CAG 'I'M: AAC ccA Ac:A G'l'G CCA GGC CCQ CAG
KYO C Q P ll: /I, Q B S B V A Q II Q Y 1'1 P T V P G P Q 79S
2359 GC.A 'l'TT '1'TA AAC AA.G TTT CI\G Me GOA QQlI. GTe MA AAT GAA At;C TAT CCA QCT GAA TTA Me AGe: AU AAT Me ACT
.A r L III It !' Q III 0 Cl V L III J: T Y PAll: L III $ I III 1'1 T 822
2467 c:AG CC'l' NX AcC CAT cn CAe cco 1'CA GAA GCC NJA CCT T'!C = GAl:: 'I'TO 1oC.A TeC AGT GGA '1'TC CN TAA 'l'!C CAA
QPTTIILBPBEAII.Pl'SDI,TB8GJ'L· 84:S
2545 GeCCATTTTTCATeT'l'GGTTTn'TGA'l'TMll.TTCGTTTGTGMACATTA'l'TAGOGAG!AA'I'MAAC'l'OTCATTGTi'GGA'rGTTAGc:AAGTTCACGTGGAGGCA
'l"1'GlI.TG'rATGTJIl:ftCm~Cll.AlI.TT'l'TAATGI\.T'l'T'MII·AAGllOt1AGTTAATTACATATAT'l'ACCATCA'1'TAAAATAGlI.,M.GV.'l'GCTGCCACA
GAGGAOTGAAlI.TAATCTACAC'I'TTATAGTJl.TTCTGI\.G1l,TACeAelIGl\ATII.':1'ACJlAA1>CTTA'l'TCAGGGGGACATTlIGGGOOACATTA'I'GA'MCT't'rTAAlLTAA
GAll,CTTT'l"l'CTCmT'I'GGAATTATTTCTG~TA/Ul,lI:tGAAATAC'l"TCGAGTTT'l'GAACTTCMCATTC'l:TAT':tAGTOT~'I'A'l'llII.ACTATT'n'CT
'l'TTA'l'TGTAGCTTCTGC'l'TTTATC'L'CAGATGTTAAAlIll'GAGNGftTGG'lGCTTT'I'ATMIIAAGA'l'lIA'l'CTCAG'tGCTe'l'CC'fCC'l'TCC'1'TGQTAATGTAAGT
GCC'l'CACAA'l'T'1'TTTCTACCTA'l'AACACTGTAGOAQTAroTTTTATATAAAATADCTTTCTCTTT'ttAAAA'l'CAATACC~CGCTCGAGCCC
TA'1AO'l'GILGTeGTATl:'&Gat.'fOGAATCGAAftCCCCGCCATGGCGGCcGGGAGCATGCGAC<lTeQGCCCAA'l'TCGCCC'l'AT
3244
Figure 3. Fun length translation of a beluga AHR eDNA. The full-length
consensus sequence of a beluga AHR is shown. Bases are numbered on the left, starting
with 1 at the start codon ATG, and encoded amino acids are numbered on the right. The
untranslated sequence is the UTR, and the stop codon is denoted with an *.
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Figure 4. Alignment of beluga, human, and mouse AHRs. The Clustal algorithm,
with slight adjustments by eye, was used to align the full-length beluga, human, and
mouse cDNAs. The functional domains labeled were identified by homology to other
mammalian AHRs (Mimura et al., 1994; Schmidt et aI., 1993; Bennett et aI., 1996).
Identical amino acids are shaded dark, similar amino acids are shaded light and boxed,
and gaps are indicated by dashes.
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Figure S. Conservation in functional domains between beluga, mouse, and
human AHRs. MacVector was used to generate pairwise alignments of the functional
domains. The boxed numbers represent percent amino acid identity within the region
spanned by the box. As with most bHLHlPAS proteins, the first nine exons that
contain the bHLH and PAS domai,ns are highly conserved, while the C-terminus is
more variable.
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Figure 6. Comparison of belAHR expression constructs under SP6 and T7
promoters. The belAHR was cloned into expression vectors under the SP6
(pSP64polyA) and T7 (pcDNA3.1) promoters. The pcDNA constructs were
constructed with and without Kozak sequences, and only the native sequence was
used to generate pSP64beIAHR(nat). Proteins were expressed in the SP6 or T7 Quick
TNT (Transcription and Translation) kits (Promega). The positive control was
luciferase (-62 kDa) that came with kits.
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Figure 7. Autoradiogram and western blot of beluga, mouse, and human AHRs.
TNT reactions that were conducted in the presence of 35S and lOOjtg cytosol protein
were run on a 7% gel. A. The Eel was dried and exposed to Kodak X-OMAT film 6
hours or 12 hours (inset lanes 1 and 2). B. Proteins were transfered to O.2jt PVDF
membrane and probed with SA-210 anti-moAHR polyclonal Ab, followed by AP-
conjugated 2° Ab, and exposed X-OMAT film for 15min. Lane 1: lOOjtg beluga liver
cytosol protein. Lane 2: lOOjtg C57/B6 mouse liver cytosol protein. Lane 3: 5jtl
pSP64 belAHR. Lane 4: 5jtl pSPORT moAHR. Lane 5: 5jtl pSPORT huAHR. Lane
6: 5jtl TNT reaction programmed with empty pSP64 vector.
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Figure 8. Velocity sedimentation analysis of in vitro-expressed and cytosol-derived
AHRs. Beluga, mouse and human AHRs were expressed in vitro and beluga and
C57BLl6 liver cytosols were incubated with 3H-TCDD, with or without 200-fold excess
cold TCDF. Total bound ['HjTCDD (DPM) are indicated by the solid boxes, and non-
specific binding (['HjTCDD that is not displaced by 200-fold excess cold TCDF) is
indicated by the hollow boxes. The specific binding detected was as follows: (A)
pSP64beIAHR 115 fmol/mg, (B) pSPORTmoAHR 185 fmol/mg, (C) pSPORThuAHR 41
fmol/mg, (D) beluga liver cytosol 7.2 fmol/mg, and (E) C57BLl6 mouse liver cytosol 24
fmol/mg. No specific binding was detected in TNT lysate programmed with empty
pSP64poiyA vector (F).
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Figure 9. Total [3H]TCDD binding and fraction of "free" relative to protein
dilution. Total binding was measured in TNT lysate progranuned with pSP64beIAHR
(squares and x's), and in unprogranuned lysate (diamonds and triangles) at different
protein dilutions. BelAHR and UPL dilutions was either treated with the same DCC
concentration at all dilution points (3.5mglml) or the DCC was adjusted at each point
to maintain the same DCC/protein ratio at all dilutions. The yellow shaded region
reflects the ideal dilution above which the fraction "free" is ideal, and the shaded
green region is the dilution for which measuring total rH]-TCDD binding is ideal.
The unshaded region of plot reflects protein dilution that best satisfies the need for
maximal fraction of "free" rH]TCDD and for maximal detection of total binding.
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Figure 10. Saturation binding curves for beluga, mouse, and human AHR. Binding
curves for A. pSP64 belAHR, B. pSPORTmoAHR, and C. pSPORThuAHR. Nine
concentrations of 3H_TCDD were incubated with TNT reaction diluted in AHR buffer as
described. Diamonds represent total binding, squares represent non-specific binding
using an empty pSP64 vector treated the same. Triangles represent specific binding
determined by subtracting the non-specific binding from the total binding. The curve
fitting the specific binding points was determined by a simultaneous fit of the binding
equations as described in the text.
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Figure 11. Scatchard analyses of saturation binding curves for
beluga and mouse AHR binding to ['H]-TCDD.
Bound + Bm" . Kds were determined by taking the inverse of
Kd KdFree
Data from Figure 10 were transformed and fitted to the linear equation:
Bound
the slope of the fitted line.
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Table I. Summary of dissociation constants (I(,,) and maximal binding (B""",) determined
for in vitro expressed AHRs. I("s of AHRs were compared using paired Student's T tests.
n Mean Kd±SD Bm",,±SD T-test with T-test with
(nM) (DPM) moAHR K" humAHR I("
_______"_"_"_"_" " .".__. "~l'2 ._~"__
belAHR 3 0.43 ± 0.16 857 ± 252 0.122 0.010
moAHR 3 0.68 ± 0.23 1322 ± 466 0.031
huAHR 3 1.63 ± 0.64 503 ± 106
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Table 2. Dissociation constants (~) reported in literatnre. Data are grouped in
columns by lab. ~s reflect ['H]-TCDD binding with the exception of data
from Poland et al., 1994, which were derived using 2-['25I]iodo-7,8-
dibromodibenzo-p-dioxin.
AHRsouree Species A1lele/line/tissue K (nM)
Translation beluga pPSP64beIAHR 0.43
products (liver)
mouse Ah'" 0.68 0.010 0.27
Ah'"
Ah' 0.037 1.66
human phuAHR 1.63 1.58
(liver HeD 02)
pSRa-hAHR 0.89
.(Hep 02 short variant)
Tissue mouse C57BL6liver cytosol 0.034 0.29 1-3~'
cvtosols (Ah"'1 Ah"')
DBA/2liver 0.09- Not 16'
cytosol (Ah' I Ah") 0.15 measur-
able
Cell human placenta 5-8'
cytosols
mouse Hepalc1c7 1.0'
(liver hepatoma)
human liverHep02 9.0'
(liver heDatoma)
LSI80 5.6'
(colon carcinoma)
A431 (squamous cell 10'
carcinoma)
BCR-5 S
(B lymphoblastoma)
Reference this a b c d, e,f.g,h,i
study
a (Poland et ai., 1994)
b (Ema et ai., 1994)
c (Gasiewicz & Rucci, 1984)
d (Manchester et ai., 1987)
e (Okey et ai., 1989)
f (Roberts et ai., 1990)
g (Harper et ai., 1991)
h (Harper et ai., 1988)
i (Waithe et ai., 1991)
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Chapter 3:
Structure-activity relationships and the derivation of relative potencies for the
binding of halogenated aromatic hydrocarbons to the beluga and
mouse aryl hydrocarbon receptors
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INTRODUCTION
Halogenated aromatic hydrocarbons (HAH) that can achieve a planar
conformation exert their toxic effects via the aryl hydrocarbon receptor (AHR) (Schmidt
& Bradfield, 1996). Mechanistic studies of AHR-dependent toxicity have focused
predominantly on 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) because it is the most
potent AHR agonist. However, TCDD is not the most prevalent HAH in the environment
by far. HAHs include the polychlorinated dibenzo-p-dioxins (PCDD), polychlorinated
dibenzofurans (PCDF), and polychlorinated biphenyls (PCB), among others. Many of
these are introduced to the environment by industrial effluents, waste incineration, or
dump seepage. Despite the curtailing of widespread manufacture of HAHs in most parts
of the world, these persistent compounds still bioaccumulate in marine organisms,
particularly in top-feeding marine mammals (AMAP, 1998).
Hundreds of HAH isomers and congeners are possible, and these differ in toxic
potency by orders of magnitude. Consequently, assessing the risk associated with
exposure to mixtures of HAH is confounding. Toxic Equivalency is a means of
simplifying the toxicity estimates for mixtures of HAH that bind to and cause toxicity via
the AHR. Because TCDD is the most toxic AHR agonist in all species examined, the
potency of other AHR-binding compounds can be expressed as fractions of dioxin
potencies, or Toxic Equivalency Factors (TEFs). TEFs are then used to adjust actual
concentrations of HAH to an expression of TCDD toxic equivalents, or TEQ (Safe,
1990). The World Health Organization (WHO) and affiliates have taken on the task of
estimating the consensus TEFs of AHR agonists for humans and wildlife. These TEFs
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are order of magnitude estimates of a compounds toxic potency relative to the toxic
potency of TCDD, and are derived from a large database of toxicity and biochemistry
data evaluated by experts. In order for a compound to be assigned a TEF, several criteria
must be met. The compound must: I) be structurally related to TCDD, 2) be persistent
and bioaccumulate in the environment, 3) bind to the AHR, 4) cause bona fide toxicity in
an organism, and 5) exert additive (rather than synergystic or antagonistic) effects (van
den Berg et al., 1998).
Recently, separate sets of TEFs were derived for birds, fish, and mammals (van
den Berg et al., 1998). However, an important weakness ofTEFs is the lack of ability to
account for species-specific differences in sensitivities to particular AHR agonists. TEFs
for mammals (including humans) have been derived almost exclusively from studies in
laboratory rodents. The primary limitation in the application of the TEF approach is
perhaps not the approach itself, but rather the lack of data that confirm the approach in a
wide variety of species and provide a reasonable estimate of error (Starr et al., 1999).
Relative potencies (REP) are toxic or biochemical responses expressed in terms of
dioxin potency. REPs can be from a single study or set of studies, and must reflect an
AHR-dependent response, though it need not be a bona fide toxic effect. The most
common effects used to determine REPs are CYPIA activity (EROD activity) and ligand
binding to the AHR. REPs can contribute to the WHO derivation of TEFs according to
the type of endpoint measured and its assessed relevance to whole-animal toxicity.
Though caution must used to avoid overinterpreting findings, REPs generated by
measuring AHR-dependent, non-toxic endpoints tend to correlate highly with REPs for
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toxic endpoints, thus supporting the TEQ concept (Safe, 1990). Compared to the number
of rodent studies, there have been very few determinations of REPs for toxicity endpoints
in feral species, though there are some notable exceptions in birds (Sanderson et aI.,
1994; Sanderson et al., 1994), fish (Mizell et al., 1996) and mammals (Deswart et al.,
1995; Hochstein et al., 1998).
As the TEF concept becomes more familiar and accepted by the scientific
community, more investigators are expressing marine mammal contaminant burdens in
terms of TEQ. In one example, total PCB burdens expressed as TEQ were shown to be
higher in striped dolphins that died during a morbillivirus epizootic compared to the
burdens in dolphins that survived (Borrell et al., 1996). In the absence of apparent
disease, some investigators have used calculated TEQ to suggest that certain populations
of cetaceans are at risk for toxic effects (Berggrena et al., 1999; Finklea et al., 2000; Ross
et al., 2000). If TEFs are to be a part of the standard language for assessing risk to
cetacean populations, it would be desirable, at minimum, to have relative potency data
that supports the use of the TEF concept for cetaceans.
The aim of this study is to determine REP for HAH binding to the beluga AHR. A
competitive binding assay was optimized for beluga and mouse TNT-expressed proteins,
and Ki values were determined for HAH inhibition of ['HjTCDD binding to the AHRs.
The Ki values were used to determine the REPs for HAH binding to beluga and mouse
AHRs. This is the first determination of REPs for a cetacean. These data contribute to
the validation of mammalian TEFs for assessing impacts in cetaceans.
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MATERIALS AND METHODS
Chemicals
2,3,7,8-Tetrachloro[I,6-'Hjdibenzo-p-dioxin (specific activity was 33.3 Ci/mmol
and purity >97%) was purchased from Chemsyn Science Laboratories (Lenexa, KS). The
unlabeled TCDD, TCDF and PCBs (IUPAC numbers 126, 169,77,81,105,118,156,
and 128) were purchased from Ultra Scientific (purity>98%). Serial dilutions of the
TCDD, TCDF, and PCBs were made in dimethylsulfoxide (DMSO) as described
previously (Hahn et al., 1996).
In vitro expression ofAHR
The mouse AHR expression construct (pSPORTmoAHR, Ahb-l allele) and human
AHR expression construct (pSPORThuAHR) were gifts from Dr. Christopher Bradfield
(Burbach et al., 1992; Dolwick et al., 1993). The beluga AHR expression vector
(pSP64beIAHR) is described in Chapter 2.
AHR proteins were expressed using the SP6 Quick TranscriptionlTranslation
system (Promega) per the supplier's instructions, with 2f.lg DNA/reaction. A TNT
reaction programmed with empty pSP64polyA vector ("unprogrammed lysate" or UPL)
was used to determine non-specific binding. For competitive binding assays, the volumes
were scaled up to 2 ml (40 reactions), then diluted with 8 parts MEEMDG buffer (35mM
MOPS, ImM EDTA, 5 mM EGTA, 0.02% NaN" 20mM NazMo04 , 10% (v:v) glycerol,
ImM DTT, pH 7.5 containing protease inhibitors). Aliquots were snap frozen in liquid
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nitrogen and stored at -80°C until use, which was usually within days. Aliquots of
expressed proteins were stored no longer than 1 month.
Competitive binding assay using dextran-coated charcoal (DCC)
The conditions for the competitive binding assay were designed to mimic the
conditions of the saturation binding assay in Chapter 2 as much as possible. The diluted
TNT reactions (150 fll) were incubated with I nM [3Hl-TCDD (nominal) and 1 fll of one
of nine concentrations (0-133 !-!M) of PHAH competitor in 16xlOO mm glass tubes. The
final DMSO concentration was always 1%. For these experiments, 1 nM [3Hl-TCDD
was chosen because it two to three times the Kd for both of the beluga and mouse binding
curves. At the start of the incubation, two 20fll aliquots were taken to measure the total
['Hl-TCDD. After a 16 hour incubation on ice, the contents of each tube were transferred
in triplicate 30fll aliquots to standard 1.5 ml polypropylene tubes containing 30 fll of 2
mg DCC/ml MEEDGM (and sometimes 20 mg/ml). Tubes were vortexed for 5 seconds
3 times, with a five minute incubation on ice between each vortexing step. Tubes were
spun at 7000g for 3 minutes, then 40fll of each supernatant was counted on a Beckman
LS5000TD scintillation counter.
Competitive binding assay using hydroxylapatite (HAP)
The HAP assay procedure was adapted from the methods of Gasiewicz and Neal
(1982), Schneider et al. (1995), and Coumailleau et aI., (1995). Diluted TNT reactions
(150 fll) were added to 16xlOO glass tubes containing ['H1TCDD (1 or 2nM nominal) and
one of 10 concentrations of unlabeled competitor (0-133 !-!M). DMSO was 1% of the
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final volume. Incubations were vortexed thoroughly and kept on ice for 16 hours (set 1)
or 8 hours (sets 2 and 3).
Following the incubation on ice, tubes were vortexed again, and 25 J1l were taken
for total counts. 150 J1l of 10% DNA grade HAP(Biorad) in MEEDMG (kept in
suspension by stirring) were distributed to 13xlOO glass culture tubes. 50J1l of the
contents of each incubation tube were added to duplicate HAP tubes and mixed by gently
vortexing until the HAP pellet was fully resuspended. Tubes were placed on ice for 30
min, with resuspension by vortexing every 10 minutes. After adding 500fll of wash
solution (MEEDMG with 0.1 % Tween 20) the tube was vortexed and spun at 1000 rpm
(approx. 300 g) for 5 min at room temperature. The supernatant was removed by
aspiration, and the pellet was washed two more times as above. After the last wash, the
pellet was resuspended in 500J1l of 95% .ethanol and transferred to a 7ml scintillation vial.
4ml Scintiverse II was added, and the disintegrations per minute (DPM) were counted on
a Beckman LS5000TD liquid scintillation counter.
Data analysis
With some exceptions (as reported in the Results), measured DPM were
converted to fractional specific (3Hl-TCDD binding:
F .(.D_P_M_-_M_S...:.:B-"-)raetlOn =-(MAX-NSB) (1)
Maximum specific binding (MAX) was defined as the binding observed when the AHR
was incubated with ['H1TCDD and DMSO with no competitor. Non-specific binding
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(NSB) was defined as the DPM obtained from unprogrammed TNT lysate incubated with
[3H]TCDD and treated with HAP as above. The binding detected using UPL was the
same as the minimum levels of binding detected when excess unlabeled TCDF is used.
The fraction of maximum specific binding points were fitted using the following
model for one-site competition:
(Top-Bottom)
Y =Bottom + 1+lOX LogICSO (2)
where Top is the fraction of CH]TCDD binding in the absence of competitor (fixed to
1.0), Bottom is the fraction of CHJTCDD binding observed when specific binding sites
are occupied with unlabeled competitor, X is the log of the concentration of competitor in
nM, and Y is the fraction of specific binding at each competitor concentration. Fits were
carried out using the mean Y value at each point, and points were not weighted. The K;
for each competitor was calculated from the IC50 and the~ of [3H]_TCDD binding
using the method of Cheng and Prusoff (Cheng & Prusoff, 1973):
K = ECso
i 1+ [ligand] .
Kd
(3)
The Kds for the beluga, mouse, and human AHR TNT were derived in Chapter 2: 0.43
nM (beluga), and 0.68 nM (mouse). All curve fitting analyses were carried out using
Prism version 2.0 for the Macintosh (GraphPad Software, San Diego).
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RESULTS
Development of a competitive binding assay for in vitro-expressed AHRs
When determining inhibition constants for competitor binding to receptors, it is
desirable that the competition assay be as similar as possible to the assay used to
determine the dissociation constant (Kd) for the compound that is to be inhibited
(Motulsky, 1999). Thus, the first approach for the development of a competitive binding
assay for in vitro expressed AHRs was to adapt the saturation binding assay with dextran-
coated charcoal (DCC) used to determine Kds for the beluga, mouse and human AHRs
(Chapter 2). All parameters were kept the same except that the radioligand (['H]-TCDD)
was kept constant and various concentrations of unlabeled competitors were added in the
incubation. During the optimization of the saturation binding assay for Kd determination,
it was observed that the beluga and human constructs lost notable amounts of specific
binding when the concentrations of DCC were in excess of I mgfml (not shown).
Consequent!y, the amount of DCC that might be required to absorb unbound TCDD plus
excess unbound competitor was a concern for the adaptation of this assay.
An example of an experminent using belAHR and TCDF as a competitor is
shown in Figure 1. When 1 mgfml DCC was used, TCDF competition for specific
binding sites appears to be 100% at approximately 80 nM TCDF. However, at higher
concentrations of TCDF, the total binding plots show that binding in fact increased,
rather than decreased in the belAHR tubes as well as the UPL tubes. There are at least
two possible explanations for the apparent increased binding at higher concentrations of
TCDF. First, the effect could be related to solubility. Total binding would appear to be
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higher if the competitor is not dissolved in the solution. However, this does not explain
why more than 100% binding is observed in the UPL, which lacks AHR, at the highest
concentrations of TCDF. Second, apparent binding could increase when the
concentration of competitor exceeds the binding capacity of the DCC. The results from
this experiment support this idea, since a lO-fold increase in DCC shifts the apparent
increase in binding to the right by approximately lO-fold.
Though the higher concentration of DCC appears to absorb a higher proportion of
excess ligand at the higher concentrations of TCDF competitor, the higher concentrations
of DCC clearly decreases the significant binding of the AHR, in agreement with earlier
observations. Taking all of these factors together, it was apparent that the competitive
binding assay using DCC was not a viable assay to use with these AHRs. Consequently,
other options were considered.
HAP is a well-established method for measuring AHR binding in rodent liver
cytosols (Gasiewicz & Neal, 1982; Gasiewicz & Rucci, 1984; Petrulis & Bunce, 2000;
Schneider et al., 1995) and has also been used with in vitro-expressed (TNT) proteins
(Coumailleau et al., 1995). These assays were modified for use with TNT-expressed
beluga proteins. HAP is a basic calcium phosphate mineral that interacts with positively
charged functional groups. Because the success of the assay depends on efficient binding
of AHR to HAP, the time of incubation and the presence of molybdate in the dilution
buffer were important factors to revisit. Upon ligand binding, the AHR "transforms" into
a DNA-binding form. All of the steps involved in transformation are not known, but the
cytosolic rat receptor gradually (2-20 hours at 200 C) changes into a form that is less
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negative and has a greater affinity for DNA (Gasiewicz & Bauman, 1987). It was
suggested recently that the term "conversion" be used to differentiate the early stages of
the AHR-ligand interaction, where the complex changes to an essentially irreversibly-
bound form, from the nuclear-localized "transformed" AHR that can interact with DNA
(Petrulis & Bunce, 2000). (Note that a "converted" form was not identified by Bradfield
et al. (Bradfield et al., 1988).)Therefore, the ability of the TNT-expressed, ligand-bound
AHRs to interact with HAP may require a time, temperature, and/or species-dependent
conversion. Thus, in the current scenario where competition experiments are to be
carried out using beluga, mouse and human AHRs side-by-side, conducting experiments
on ice, rather than room temperature (slowing conversion?) would seem to favor
opportunity for competition to reach equilibrium.
The molybdate ion stabilizes the AHR in a species-specific manner. Molybdate is
particularly necessary for stabilizing the human AHR and the low affinity mouse (Ahd)
AHR so they it may be characterized in binding studies (Manchester et al., 1987) (Golas
et al., 1990; Okey et aI., 1989; Roberts et al., 1990). In contrast, molybdate contributes
to destabilization of the rat AHR (Kester & Gasiewicz, 1987). Stabilization by
molybdate allowed the successful analysis of the Kd of beluga, mouse, and human AHRs
by saturation binding when DCC was used to separate bound ligand from free ligand
(Chapter 2). However, molybdate also inhibits AHR transformation at the level of
ARNT dimerization by stabilizing the AHR-hsp90 association at a threshold
concentration around 20 mM (Heid et al., 2000). Since the biochemical changes that lead
to hsp90 dissociation, and the physiochemical requirements for AHR-HAP association
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are not known, it was unclear whether molybdate would inhibit AHR association with
HAP.
Figure 2 shows the time course and effect of molybdate on specific binding of
beluga, mouse and human AHRs at two concentrations of ['H]-TCDD and 200-fold
excess TCDF. Molybdate increased detectable specific binding in all AHRs, not just the
human AHR. In most cases, maximal specific binding was reached at 8 hours. Despite
the benefits of molybdate, the specific binding observed for the human AHR was very
low relative to mouse and beluga binding. Non-specific binding, as determined by
competition with 200-fold excess TCDF, varied only with ['H]-TCDD concentration, and
not with AHR species origin, molybdate presence, or time. A summary of parameters
used in this HAP assay alongside parameters published in other studies is in Table 1.
Competitive inhibition studies with beluga and mouse AHRs
The HAP assay described above was used in competitive inhibition studies on the
beluga, mouse, and human AHRs for the purpose of deriving structure-activity
relationships using various HAH compounds. Five different structure classes of HAH
were represented: TCDD (PCDD), TCDF (PCDF), IUPAC 126, 169,77, and 81 (non-
ortho PCBs), IUPAC 105, 118, 156 (mono-ortho PCBs), and IUPAC 128 (di-ortho
PCBs). Three sets of competitive inhibition curves were generated. One set was obtained
with selected members of each HAH structure class listed above at 1 nM ['H]-TCDD
with no molybdate in the dilution buffer. Two sets were carried out at 2 nM ['H]-TCDD
with molybdate in the dilution buffer (Table 2).
92
Representative competitive inhibition curves generated for beluga and mouse
AHRs are shown in Figure 3. The data were fit to a one-site competition model (Equation
2), and the curves were derived by fixing the values of the tops and bottoms of the model
to 100% and 0% specific binding. The rationale for fixing the parameters of the curve fit
is as follows. Because the data points are expressed as fractional specific binding, the
only way that a one-site competition model can be correct is if the actual minimum of the
curve is 0%. In practice, the actual concentration of competitor needed to displace >95%
of ['H]-TCDD specific binding may be greater than the highest concentrations tested, and
perhaps beyond the limits of solubility. By allowing the model to fit the data points
assuming that 100% inhibition is possible, the equation is able to predict an IC50 that is
based on the data points yet is not underestimated because of solubility limitations and
false minima.
Table 2 lists the IC50s for curves fit to the data with fixing the top and bottom of
the curves to 100% and 0% specific binding (column 1) and without fixing these
parameters (column 2). Also listed in Table 2 are the model-fitted lower plateaus of the
curves (Column 5), as well as the lowest fraction of specific binding measured in each
experiment (Column 4). Comparing these values for each compound shows that, in
general, the derived IC50s from both sets of curve fitting parameters were in close
agreement for compounds that compete well for AHR binding (e.g. TCDD,126, 81). For
compounds that did not compete as well for ['H]-TCDD binding (e.g. 105, 118) the fitted
curve minimum (column 5) was far from 0%, and the IC50s calculated from the "fixed"
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fits (column 1) tended to be higher than those estimated from the "unfixed"fits (column
2).
The IC50s spanned 5 orders of magnitude, and the rank order of the IC50s for
beluga AHR binding was: TCDD<TCDF<126<169<77<81<<<156-128<105<118. The
rank order of IC50s for the mouse AHR binding was TCDD<TCDF<
126<169<81<77<156«128-105-118.
Inhibition constants (Ki) were generated based on the IC50s from the curves with
fixed tops and bottoms (column 1), the Kds for the beluga and mouse AHRs (Chapter 2),
and the ['H]-TCDD incubation concentration. K.;s are unique to a specific receptor and
compound, and should independent of radioligand incubation concentrations. Therefore,
K.;s can be compared across experiments, assuming the experiments were conducted
under similar conditions. The individuallogK.;s for each compound and for each species
are plotted in Figure 4, and summarized numerically as Ki in Table 3. TCDD was the
competitor with the highest affinity for both AHRs. The average Ki for TCDD in beluga
was 0.1 nM, and for mouse the mean Ki for TCDD was 0.36. These are in close
agreement with the Kds determined for TCDD binding using a saturation binding assay,
0.43 nM for beluga AHR, and 0.68 nM for mouse AHR. TCDF also had a very high
affinity for both AHRs. As a group, the binding affinities of the non-ortho substituted
PCBs spanned an order of magnitude in beluga (1.6-19 nM), and slightly more for the
mouse AHR (4.6-94 nM). All of the non-ortho PCBs had a binding affinity that was less
than TCDD and TCDF, but greater than the mono or di-ortho PCBs. Of these 4 non-ortho
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PCBs, PCB 126 clearly had the highest affinity for both AHRs. pCBn, 169, and 81 all
had very similar Ki values for both AHRs that ranged a few fold.
Among the mono-ortho PCBs, PCB 156 had the highest affinity for both AHRs.
PCB 105 and 118 had higher Ki values than PCB 156. The Ki values for 105 and 118
were very similar to each other in either species. The Ki for the mono-ortho were one or
two orders of magnitude higher than the non-ortho PCBs. The one di-ortho PCB that was
tested, PCB 128, had an affinity for the beluga AHR that was very similar to that of
PCB 156. In the mouse, the affinity of PCB 128 was very similar to those of PCBs 105
and 118. Attempts to use another di-ortho PCB (PCB 170) in the competitive binding
assay failed because of insolubility.
Relative potencies for AHR binding were determined from the mean Ki values for
each HAH (Table 3). The REPs span 5 orders of magnitude in the beluga (1-0.00007),
and 4 orders of magnitude for the mouse (1-0.0002). The compound with the lowest REP
for beluga for mouse was mono-ortho PCBI18.
The HAP competitive binding assay was also used in attempts to derive HAH Ki
values for the in vitro-expressed human AHR. Despite several repeats and trials with
alternate conditions, data were scattered and uninterpretable. This is consistent with
other investigators' inability to obtain data using the HAP assay with human placenta
(Nakai & Bunce, 1995). Because the TNT products generated binding curves that were
sufficient for the derivation of Kds (Chapter 2), it seems probable that the difficulty lies in
the association of the human AHR with the HAP, rather than instability of the human
AHR protein under these conditions.
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DISCUSSION
Since PCBs were discovered at very high concentrations in marine mammals in
the 1970s, there has been concern about the possible effects on marine mammal health.
A growing number of observations suggests that contaminant burdens can have negative
effects on cetacean health. Cetaceans and seals that succumb to disease tend to have
significantly higher contaminant body burdens compared to animals that survive
epizootics or die from incidental take (Aguilar & Borrell, 1994; Hall et al., 1992; Jepson
et al., 1999). Despite lack of proof of AHR-mediated toxicity in marine mammals, the
tendency to express marine mammal contaminant burdens as TEQ is on the rise. Thus, in
order to further the characterization of the beluga AHR and begin to establish an
experimental basis for the application of the TEF concept to cetaceans, competitive
inhibition studies were conducted to measure binding affinities of and derive REPs for
HAH binding to the beluga AHR. For comparison, the well-studied mouse Ahb-I allele
was included in the analysis. This is the first determination of relative potencies of any
kind for a marine mammal, and the most comprehensive set of relative potencies derived
for HAH binding in vitro to mouse AHR.
Determination ofrelative potencies for beluga and mouse AHR
A HAP assay was modified for use with beluga and mouse TNT products to
determine structure-binding relationships for various representative classes of HAH: the
polychlorinated dibenzo-p-dioxins (PCDD), the polychlorinated dibenzofurans (PCDF),
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non-ortho PCBs, mono-ortho PCBs, and di-ortho PCBs. All of these HAH structure
classes are found in the environment and detected in marine mammal tissues, including
beluga (Martineau et aI., 1987). Competitive binding curves show that all of the HAHs
tested were able to displace ['H]-TCDD for AHR binding (Figure 3). The K.i values
calculated for HAH inhibition of ['H]-TCDD binding to beluga and mouse AHRs shared
a very similar rank order overall and within HAH structure groups (Table 3). These in
tum were very similar to the rank order of IC50 values determined for inhibition in rat
hepatic cytosol (Bandiera et al., 1982). The similarity of the structure-binding
relationships of the beluga AHR compared with those of rodent AHRs suggests that the
structure requirements for high affinity ligand binding are very similar among these
AHRs.
For the beluga and mouse AHRs, the three mono-ortho and the single di-ortho
PCBs examined had similar affinities that were had much lower than the affinities of the
coplanar HAHs. It was somewhat surprising to observe that the di-ortho PCBI28 had a
binding affinity that was similar to or greater than some of the mono-ortho PCBs.
Binding studies with rat cytosols have shown that di-ortho PCBs tend to have IC50s that
are one to two orders of magnitude greater than the mono-ortho congeners (Bandiera et
aI., 1982). In contrast, PCB 128 binds to a fish AHR with the same affinity as PCB 105
and 118 (Hestermann et al., 2000). In this study, the ability of PCB 128 to inhibit ['H]-
TCDD binding was not an artifact of curve fitting to few points, since PCB 128
competition reached 90% for beluga AHR and 80% for mouse AHR. Also, the curves
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generated by the one-site competition model (with the exception of one mouse
experiment) fit the data very well.
The high affinity binding by PCB 128 to the beluga and mouse AHRs may not be
a contradiction given that receptor binding does not always result in receptor activation.
The ability of a compound to cause an effect beyond receptor binding is referred to as the
efficacy of a compound. Tissue-specific contributions to the mediation of the AHR-
generated signal is called "coupling" (Kenakin, 1999). The validity of the TEF concept
depends on high efficacy of AHR ligands. Rodent data suggest that in general, di-ortho
PCBs bind to the AHR with low affinity but do not elicit in vivo toxic or biochemical
effects (Goldstein & Safe, 1989). In the past, very low TEFs (0.0001-0.00001) were
assigned to di-ortho PCBs by the WHO (Ahlborg et al., 1994). The most recent WHO
report withdrew TEFs for di-ortho PCBs because of a lack of AHR-dependent toxicity
data (van den Berg et al., 1998). More recent studies have shown that di-ortho PCBs can
elicit competitive antagonism of ligand binding and downstream responses of more
potent AHR agonists (Hestermann et al., 2000; Petrulis & Bunce, 2000). Further, some
antagonistic effects by di-ortho PCBs may be species-specific (Aarts et ai., 1995).
The WHO-98 TEFs are presented alongside REPs for beluga AHR binding,
mouse AHR binding, and rat AHR binding (Table 4). Comparing the REPs with the
TEFs in this table demonstrate that for the most potent AHR agonists, REPs reflect TEFs
quite well. For mono- and di-ortho PCBs, however, REPs display species specificity and
may not correspond as well to the suggested mammalian TEF.
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Overall, the structure-activity relationships observed by HAH binding to the
beluga AHR support a similar mechanism of toxicity to that observed in the mouse. The
Ki values and REPs calculated for the binding of HAH to the beluga AHR are consistent
with the ability of coplanar PCBs to activate the beluga AHR and cause downstream
responses such as toxicity and CYPIA induction. There are cetacean field data to
support this assertion. A number of investigators have reported relative depletion of
coplanar HAH among the suite of HAH detected in cetacean tissues, and all have
suggested that this is indicative of a high capacity for CYPIA-dependent metabolism in
cetaceans (Boon et al., 1997; Kannan et al., 1989; Norstrom et al., 1992; Tanabe et al.,
1988). The occurrence of CYPIA has been confirmed in cetaceans, including minke
(Gokspyr et al., 1988) and beluga (White et al., 1994). In the beluga study, CYPIA
protein levels correlated well with the concentrations of non and mono-ortho PCBs in
these animals. This observation for feral beluga, along with the observations of high
affinity binding of HAH with beluga AHR, suggest that coplanar HAH display high
potency for binding that is coupled with efficacy for downstream effects in the beluga.
This supports the application of mammalian TEFs for these compounds to cetaceans.
An important factor that can be easily overlooked in discussions of species-
specific relative potencies is absolute differences in sensitivity. Beyond structure activity
relationships, another potentially important observation is that the absolute binding
affinities of HAH for the beluga AHR were consistently several fold higher than those of
the mouse. This is especially true for TCDD and PCBs 126, 77, 81, and 128, for which
the 95% confidence intervals for the binding Ki do not overlap those of mouse AHR. An
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exception to this pattern was PCB 156, which had nearly identical Ki values in both
species. Thus, the beluga AHR has a higher affinity than mouse AHR for most of the
HAHs tested; this is consistent with the -2-fold higher beluga AHR [3H]-TCDD binding
affinity determined by saturation binding. Differences in absolute TCDD binding
affinities among mouse AHR alleles in vitro correspond with differences in overall strain
sensitivity in the homozygous mice (Poland et al., 1994). Thus, for two species that
differ in overall sensitivity to AHR ligands, the same TEQ measured in two different
species might be an order of magnitude more potent in one compared to the other.
In summary, a competitive binding assay was used to determine the ability of
several structure classes of HAH to inhibit binding to the beluga and mouse AHRs. The
inhibition coefficients indicated high affinity HAH binding by both receptors, particularly
for the coplanar HAH. Together with available field and in vitro data, these results
suggest that the beluga AHR has a high affinity for coplanar HAH that is coupled with an
efficient CYPIA metabolic response. Thus the application of the TEF for coplanar HAH
to cetaceans seems valid. The advice of the WHO-98 to revoke TEFs for di-ortho PCBs
should be upheld until toxicity data for cetaceans becomes available. These results also
demonstrate the value of molecular and in vitro approaches for addressing toxicological
questions in protected species for which dosing is impossible.
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Figure 1. Competitive binding assay with dextran-coated charcoal (DCC).
Incubations with TNT-expressed beluga AHR (be1AHR) and unprogrammed
lysate (UPL) diluted in buffer were carried out in 1 nM rHJ-TCDD and various
concentrations of TCDF. The incubations were treated with 1 mglml
or 10 mglml DCC, centrifuged, and the DPM of the supernatants were
counted. A. Total binding for belAHR and upl. B. Specific binding of
belAHR, determined by the difference between the belAHR total binding and
the Upl curve at both charcoal concentrations.
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Figure 2. HAP assay timecourse and effects of sodium molybdate on specific
binding of beluga, moose, and hmnan AHRs. In vitro-expressed proteins were
incubated with I nM or 2 nM [3H]-TCDD, with or without 17 rnM NaMo04.
Non-specific binding was subtracted from total binding and the resulting DPM
were plotted. The non-specific binding was determined with 2oo-fold excess
TCDF, and varied only with [3H]-TCDD concentration, and not with AHR
species origin, molybdate, or time.
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Figure 3. Competitive binding curves for mouse and beluga AHR for
various HAH. Inhibition of binding of 2 nM rHl-TCDD to beluga and mouse
AHRs by various HAH was measured by the HAP assay. Curve maxima and
minima were fixed to 100% and 0% and fit to a one-site competition model
using non-linear curve fitting. IC50s were calculated for TCDD, TCDF, and
PCBs (IUPAC numbers 126, 169,77,81, 105, 118, 156, 128). Error bars
represent 1 SD.
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Figure 4. Inhibition constants (KJ of (3H]_TCDD binding to beluga and
monse AHRs by various HAH. lCSOs were determined from the non-linear
curve fit to a one-site competition model, and K; values were determined by the
method of Cheng and Prusoff. Bars represent means of logK; determinations
for beluga AHR (hatched), or mouse AHR (solid). Whiskers indicate 1 standard
deviation.
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Table 1. Comparison of parameters used in competitive binding assays using hydroxylapatite absorption.
Coumailleau et al. Schneider et at , Gasiewicz and
Parameter this assay 1995 1995 Neal, 1984
sample type TNT products TNT products liver cytosols liver cytosols
non-specific binding UPL 250-fold excess TCDF 2oo-fold excess TCDF 2oo-fold excess TCDF
protein concentration in incubation 1.3 mg/ml ~3 mg/ml not reported 1.5-2.5 mg/ml
buffer MEEDMG TEa HEDG HEDG
[AHR] in incubation <.05nM not reported <0.2nM ~.05-0.12nM
[3H]-TCDD in incubation 0.9-1.6nM 0.2-2.5nM 1nM 0.3 nM
[3H]-TCDD specific activity 33 Ci/mmol 28Ci/mmol 37Ci/mmol 50.5 Ci/mmol
..... % solvent in incubation I%DMSO not reported 2%DMSO 0.5% dioxane0
U>
incubation time 8-16 hours 90 minutes 1 hour 2 hours
incubation temperature 0_4° C RT RT 20°C
detergent in HAP wash 0.1% Tween 20 0.1% Tween 20 1% Triton X-1OO 1% Tween 80
number washes of HAP 3 4 4 4
DCC adsorption step none 70mg/ml none none
volume wash:vol incubation in HAl 30 3 mg/ml 20 20
MEEDGM: 35mM MOPS, 1mM EDTA, 5 mM EGTA, 0.02% NaN3, 20mM Na2Mo04, 10% glycerol, (pH 7.5),
1mM dithiothreitol, plus protease inhibitors
TEG: 20 mM Tris-HCl pH 7.4,1 mM EDTA, 10% glycerol, 1 mM dithiothreitol
HEDG: 25 mM Hepes pH 7.4, 1.5 mM EDTA, 10 % glycerol, 1 mM dithiothreitol
Table 2. Summary of competitive binding experinients (HAP assay).
BELUGA MOUSE
.....
~
""'-, I.
""
, ...........-"" .... ",.'
Ki lowest fitted Runs Test Ki lowest fitted Runs Test I
HAH: loglCSO 1 loglC50 2 (oM) • data pt 4 curve min s RA2tl (p) , loglC50 , I09lC50 2 (oM) • data pt .. curve min 5 RAZe (p) ,
TCCD - - - - - - - - - -
- -
.
-
TCDF 0.09 0.09 0.39 0.00 0.31 0.98 0.71 0.78 0.62 2.6 0.12 0.08 0.95 0.14
126 0.53 0.53 1.5 om 0.10 0.95 0.88 1.2 1.1 6.4 0.10 0.09 0.96 0.64
169 1.6 1.1 14 0.26 0.23 0.66 0.25 2.5 1.1 122 0.47 0.47 -0.24 0.07
77 1.4 1.2 7.3 0.01 0.11 0.94 0.37 2.6 2 172 0.31 0.29 0.87 0.07
81 - - - - - - - - - - - - . -
105 3 3 315 0.27 0.08 0.73 0.11 3.7 3.3 2175 0.37 0.27 0.94 0.64
118 3.7 2.9 1595 0.37 0.39 0.8 0.25 4.3 3.9 8873 0.53 0.12 0.24 0.2
156
- - - - - -
.
128 2.9 3.1 258 0.05 -0.03 0.93 0.28 C' 3.3 0.05 858 0.31 0.55 -1.2 0.83
SET 2: r3H TCDD= 1.6 oM
Ki lowest fitted Runs Test KI lowest fitted Runs Test I
loglC50 , loglC50 , (oM) • data pt .. curve min 5 RAZ 8 (p) , loglC50 , loglC50 , (oM) • data pt .. curve min 5 RA26 (p) ,
TCCD -0.15 -0.16 0.15 0.10 0.11 0.93 0-07 0.16 0.3 0.43 0.03 0.06 0.88 0.04
TCDF 0.13 0.17 0.28 0.04 0.05 0.95 0.19 0.21 0.33 0.49 0.06 0.05 0.92 om
126 0.82 0.82 1.4 0.02 0.02 0.98 1 1 0.94 3.2 0.05 0.09 0.97 0.4
169 1.3 1 4.3 0.06 0.21 0.75 0.11 1.6 1.1 10.8 0.09 0.25 0.62 0.05
77 1.6 1.2 8 0.18 0.22 0.71 om 2.2 1.7 52.1 0.21 0.27 0.78 0.05
81 1.9 1.8 15.4 0.08 0.07 0.98 0.29 2 1.9 32 0.06 0.11 0.89 0.22
105 3.7 4.1 1016 0.23 -0.42 0.78 0.58 3.5 3.2 917 0.34 0.27 0.77 0.08
118 3.9 4 1842 0.38 -0.13 0.93 0.88 3.8 3.8 2051 0.35 0.01 0.89 0.79
156 3.3 2.8 388 0.33 0.29 0.84 0.5 2.9 2.6 229 0.28 0.26 0.62 0.05
128 3.4 2.9 567 0.34 0.29 0.83 0.79 3.7 3.1 1496 0.43 0.38 0.87 0.63
......
S
SET 3: {3H1TCDD= 1.6 nM
Ki lowest fitted Runs Test ~~ Ki lowest fitted Runs Test
loglC50 1 loglC50 2 (nM) , data pt 4 curve min 5 RA26 (p) 7 :1:<1 loglCSO T 1091C50 2 (nM) • data pt .. curve min s RJ',26 (p) ,
TCDD -0.5 -0.5 0.07 0.04 0.1 S 0.77 0.1 (f.' 0.002 0.17 0.3 0.02 0.05 0.92 0.07
TCDF k::T~rZ);
126 1 0.87 2.1 0.02 0.04 0.97 0.28 M.i 1.2 0.96 4.7 0.09 0.09 0.96 0.22
169 1.5 1.2 7.1 0.15 0.25 0.68 0.26 r~0; 2 1.3 27.6 0.07 0.30 0.5 0.04
77 1.6 1.5 8.1 0.16 0.13 0.95 0.8 ~ii 2.5 2 91.7 0.22 0.26 0.82 0.0581 2 1.9 22.4 0,02 0.05 0.99 0.22 2.1 2 36.2 0.01 0.06 0.98 0,07
105 3.4 2.9 569 0.34 0.33 0.81 0.08 t~1 3.9 2.7 2131 0.45 0,51 0.7 0,25
118 3.7 3,5 1010 0.35 0.22 0.77 0,08 I 3.8 3.4 1781 0.35 0.25 0.9 1156 3.1 2.9 245 0,21 0,18 0.9 0,08 3.1 2,6 352 0,32 0.29 0,82 0.4128 3,3 3 388 0,12 0,15 0,94 0.37 3,9 3,7 2233 0,24 0,20 0,86 0.4
1. loglC50 (1): determined by non-linear curve fitting to a one-site model for competition, with the values for top and bottom of the curves fixed at 100% and 0%, respectively.
2. I09IC50(2): determined by non-linear curve fitting to a one-site model for competition, and t~e model fitted values for the maximum and minimum fractional specific binding
3. Ki (oM): determined by the method of Cheng and Prusoft from the loglC50 (1).
4. Lowest data point: the lowest average fractional specific binding point determined for this curve
S. Fitted curve min: lowest fractional specific binding as determined by one~site competition model without fixing top and bottom values
6, RA2: R~square for the.one·site competition model used to determine logICSO(l)
7. Runs test: a reflection of how well the model fits the data based on how many consecutive data points run above or below the fitted curve, regardless of R·square.
If p<,OS, then significant chance a different model would better fit the data,
......
o
00
Table 3. Summary of IC50s, Ki, and relative potencies determined for beluga and mouse.
Mean IC50 is the average of the two experiments conducted at 1.6 nM, and Mean Ki is determined from all three data sets.
Beluga Mouse
Mean IC50 Mean Ki 95% confidence Relative potency Mean IC50 Mean Ki 95% confidence Relative potency
HAH Chlorination pattern (nM) (nM) interval for Ki (from mean Ki) (nM) (nM) interval for Ki (from mean Kil
TCDD 2,3,7,8, 0.47 0.10 0.05-0.22 1.00 1.21 0.36 0.25-0.51 1.00
TCDF 2,3,7,8, 1.35 0.33 0.24-0.46 0.31 1.62 1.1 0.21 -5.8 0.32
126 3,3',4,4',5 8.1 1.6 1.3-2.1 0.063 12.6 4.6 3.1-6.8 0.078
169 3,3',4,4\ 5, 5' 25.1 7.5 3.9-14.7 0.014 63.1 33 8.3-132 0.011
77 3,3',4,4' 35.5 7.8 7.3-8.3 0.013 224 94 47.6-185.1 0.0038
81 3,4,4',5 89.1 19 12.9-26.8 0.0055 112 34 30-38 0,01 1
105 2,3,3',4.4' 3548 567 292-1099 0.00018 5012 1620 927-2829 0.00022
118 2,3',4,4', 5 6310 1437 930-2219 0.000071 6310 3188 930-10934 0.00011
156 2,3.3',4,4',5 1585 309 196-485 0.00033 1000 284 186-433 0.0013
128 2,2',3,3',4,4' 2239 384 246-600 0.00027 6310 1421 826-2445 0.00025
Table 4. Relative potencies (REPs) for AHR binding and mammalian Toxic Equivalency
Factors (TEFs) ,
beluga REPs for mouse REPs for rat REPs for 98 WHO TEFs for
b AHR b d' 'Idl'f Ih
Chlorination
HAH oattem AHR indina AHRbindina in inS 1 WI ,. umans 2;
TeDD 2,3,7,8, 1.00 1.00 1.0 1
TeDF 2,3,7,8, 0.31 0.32 0.1
126 3, 3t, 4, 4', 5 0.063 0.078 0.08 0.1
169 3,3',4,4',5,5' 0.014 0.011 insoluble 0.Q1
77 3,3',4,4' 0.013 0.0038 0.Q1 0.0001
81 3,4,4\ 5 0.0055 0.Q11 0.0004 0.0001
105 2,3,3',4,4' 0.00018 0.00022 0.0023 0.0001
118 2, 3',4,4', 5 0.000071 0.00011 0.0011 0.0001
156 2, 3, 3', 4, 4', 5 0.00033 0.0013 0.0014 0.0005
128 2,2',3,3',4,4' 0.00027 0.00025 - -
I calculated from ICSO reported in Bandiera et al., 1982
2; van den Berg et al., 1998
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Chapter 4:
Tissue-specific expression of the aryl hydrocarbon
receptor in the beluga
111
INTRODUCTION
Dioxins and related planar halogenated aromatic hydrocarbons (PHAH) are
known to cause a variety of toxic effects in terrestrial mammals, including
immunosuppression, thymic atrophy, reproductive toxicity, cancer, epithelial hyperplasia,
enzyme induction, and wasting syndrome (Schmidt & Bradfield, 1996). Studies using
mice that that do not express the AHR have shown that the AHR is necessary for these
toxic effects to occur (Fernandez-Salguero et at., 1996; Hundeiker et at., 1999).
High body burdens of contaminants in marine mammals correlate with episodes
of disease and low rates of reproduction in certain cetacean populations (reviewed in
Chapter 1). This has raised questions regarding the possible health effects of
contaminants in cetaceans. However, a mechanistic link remains to be established
between contaminant exposure and observed effects in feral cetacean populations.
The AHR is very likely to be an important protein in this mechanistic link.
Chapters 2 and 3 describe the isolation and characterization of a beluga AHR, and the
expressed AHR protein was used to compare relative binding affinities among species
and to determine structure-binding relationships for different PHAH. These results
showed that the beluga AHR binds to PHAH with the same structure-activity
relationships that have been established for other mammals, but the overall affinity for
the compounds is greater. In this chapter, another factor involved in establishing the link
between cetacean disease and PHAH exposure is addressed by examining the tissue-
specific expression of AHR in beluga tissues.
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There is theoretical and experimental support for the argument that relative AHR
expression can predict sensitivity to AHR agonists. For example, Kenakin (1999) noted
that "The number of units (receptors) capable of producing stimuli in the organ clearly is
a factor in the total stimulus imparted by any concentration of agonist. ..Therefore, the
higher the number of drug receptors [R,] is, the larger the receptor stimulus"(Kenakin,
1999).
The radiation chimeric mouse is an elegant model that shows the importance of
tissue and cell-specific AHR expression for determining PHAH toxicity. Irradiated
Ah+/Ah+ mice were reconstituted with Ah)Ah- bone marrow stem cells, and the
reciprocal case was also done. Mice that were reconsituted with Ah-/Ah- hematopoetic
stem cells, regardless of background phenotype of the stromal cells, were resistant to
TCDD-induced thymic atrophy and suppression of the B-cell maturation process (Staples
et al., 1998; Thurmond et al., 2000). Though the mechanism is not known, it appears to
involve the disruption of signaling events during proper proliferation and differentiation
stages, and growing evidence is implicating the involvement of the transcription factor
NFkB (Puga et al., 2000; Tian et al., 1999). Pre-B cells in the bone marrow are also
targets of another pathway of AHR-mediated toxicity. 7,12-Dimethylbenzanthrazene
causes pre-B cells to undergo apoptosis following a signal generated from bone marrow
stromal cells. The "death signal" is dependent on AHR induction of cypm1, thus
implicating a CYPIBI metabolite (Heidel et aI., 1999; Mann et al., 1999).
Other mechanisms likely occur in other tissues and cell types. For example,
planar representatives of the polyaromatic hydrocarbons (PAH) such as benzo[a]pyrene
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(B[a]P) bind to the AHR and induce CYP1A1 and CYPlB1 that metabolize PAR.
Certain of these metabolites, particularly B[a]P-7,8-diol-9,1O epoxide (BPDE), are highly
genotoxic, and are implicated in cancer initiation in many tissues, including liver and
lung (Phillips, 1983). It was shown recently that B[alP induced carcinogenicity is strictly
AHR-dependent, which confirms exclusive roles for CYP1A1 in producing genotoxic
B[a]P metabolites, and reconfirms the AHR in the induction of CYP1A1 (Shimizu et ai.,
2000). Though TCDD is not a tumor initiator (a genotoxin), it is known to be an
extremely potent tumor promoter (Ruff et al., 1994; Pitot et al., 1980). Furthermore, it
was recently shown that a genotoxic class of PAR metabolites (planar PAR o-quinones)
can bind the AHR and be translocated into the nucleus, thereby using the AHR as a
"shuttle" for nuclear targeting by carcinogens (Burczynski & Penning, 2000). Thus, it is
clear that certain organs and cells are sensitive targets of PRAR, planar PAR, and certain
PAR metabolites, and the sensitivity is AHR-dependent.
Pathologies similar to those observed in rodents treated with AHR agonists occur
in beluga of the St. Lawrence Estuary. Cancer has been reported in many of the small
beluga population of the St. Lawrence Estuary, Canada. Tumors were detected in 40% of
the 45 belugas necropsied (Beland et aI., 1993). Of these, 9 malignant cancers occurred
in bladder, ovary (2 animals), salivary gland (2 animals), stomach, intestine (2 animals),
and liver. This is coincident with B[a]P adducts detected in 90% of the animals tested
(Martineau et aI., 1994). This high incidence of cancer, along with high frequencies of
viral and bacterial infections suggest that St. Lawrence beluga may also suffer from
immunosuppression (Deguise et al., 1995). All of these pathologies are coincident with
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high chemical burdens in beluga tissues, of which PHAH are represented (Martineau et
al., 1987). Thus, the targets for PHAH and other AHR ligands in beluga might be similar
to targets in rodents.
In order to begin to assess potential sites for AHR-mediated toxic effects in
cetaceans, the tissue-specific expression of AHR was examined in the beluga. Several
tissues were collected from 5 male beluga from the Alaskan Arctic. Three methods were
used to measure AHR expression: 1) ligand binding in cytosols, 2) presence of
imrnunodetectable AHR protein in cytosols, and 3) messenger RNA expression. These
results provide insights about AHR regulation and implicate potential targets for PHAH
toxicity in the beluga.
MATERIALS AND METHODS:
Sample collection
The beluga tissues were collected during and after subsistence hunts by native
American Inupiaq. The first collection was after an opportunistic take in Barrow, AK in
July 1997, after the organized annual hunt in Point Lay, AK was spoiled by unfavorable
ice conditions. After the blubber (maq taq) and meat were taken by the hunters, most of
the inner viscera from 3 male belugas were bagged in plastic and kept outside
(temperature O-SO C) until sampling began about 3 hours later. 97-1 was sampled first,
followed by 97-2 and 97-3. The last frozen samples were taken about 2 hours after
sampling began, approximately 5 hours post-mortem.
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The second sampling opportunity occurred during the organized annual hunt in
Point Lay in July, 1998. The belugas were killed by bullet fired into the rear of the
cranium at close range. After the belugas were towed ashore and pulled up onto the
beach, two of the youngest looking animals (as judged by their color) were chosen for
sampling. 98-1 had the most grey character (indicating that it may be 1 year old or less)
followed by 98-2. The time post mortem before sampling began on 98-1 was 1.5-2
hours. The approximate order for tissue sampling in 98-1 was liver, lung, heart, thymus,
spleen, lymph node, testis, thyroid. Beluga 98-2 was sampled immediately after 98-1,
about 1 hour later, 2.5-3 hours post mortem. The approximate order of sampling was
liver, lung, heart, spleen, kidney, adrenal, testis, thyroid. Again, sampling took
approximately one hour. Tissues were cut into small slices, placed in pre-labeled 2 ml
cryo vials, and snap frozen in liquid nitrogen until further processing.
Cytosol preparation
Liver cytosol was prepared as described in Hahn et al (1994). Cryo-preserved
liver was first powdered under liquid nitrogen temperatures, then homogenized in
MEEDGM (35mM MOPS, 1mM EDTA, 5 mM EGTA, 0.02% NaN" 20mM NazMo04 ,
10% (v:v) glycerol, 1mM DTT, pH 7.5 containing protease inhibitors and PMSF) with at
least 20 passes of a teflon pestle, keeping the sample cool with a beaker of ice. After
serial centrifugations of 750g, 12,000g, and 100,000g, the supernatants were snap frozen
and stored in liquid nitrogen until analysis. Protein concentrations were determined by
the method of Lorenzen and Kennedy (Lorenzen & Kennedy, 1993). Bovine serum
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albumin standards and samples were read in triplicate and MEEDGM was used as the
blank.
In vitro expression
The beluga AHR (pSP64beIAHR) was constructed as described in Chapter 2.
The mouse AHR (pSPORTmoAHR) was a gift from Dr. C. A. Bradfield (Burbach et al.,
1992). The mouse AHR repressor construct was a gift from Dr. Y. Fujii-Kuriyama
(Mimura et al., 1999). Proteins were expressed from ultrapure vector in a rabbit
reticulocyte lysate: TNT T7 or SP6 Quick Coupled Transcription and Translation Kit
(Promega,Madison, VVI)
Velocity sedimentation
The velocity sedimentation procedure follows the vertical tube rotor method of
Tsui and Okey (Tsui & Okey, 1981). 2,3,7,8-Tetrachloro[I,6-'H]dibenzo-p-dioxin,
specific activity 27 Ci/mmol (['Hl-TCDD) was purchased from Chemsyn Science
Laboratories (Lenexa, KS). ['H]-TCDD in DMSO, plus either DMSO or 801JM TCDF in
DMSO were added to 300fJl of undiluted chipped cytosols (1.2-2.9 mg protein), to final
concentrations of 2nM ['Hl-TCDD ± 400nM TCDF and 1% DMSO in 13xlOO glass
culture tubes. A 50 fJl (1.2 mg protein) pSP64belAHR TNT reaction diluted in 2 parts
MEEDGM and incubated with the same final concentrations of ['H]-TCDD and TCDF.
Tubes were parafilmed, vortexed, and placed on ice. After 2 hours, 25 fJl were taken for
total counts, and the remainder of the reaction was transferred to a polypropylene 1.5ml
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microcentrifge tube, vortexed for 10 seconds, and tap spun. 275 flI of cytosol incubations
and 125 /-11 TNT incubations were applied to 10-30% sucrose gradients that were
prepared in MEEDMG buffer using the method of Coombs and Watts (1985) in Beckman
polypropylene centrifuge tubes. 5 flI of a mixture of [14C]-Ovalbumin (3.6 S) and e4C]-
catalase (11.3 S) were loaded on the gradient as internal sedimentation markers. The
gradients were spun for 140 min at 60,000 rpm at 4°C in a VTi 65.2 rotor. The gradients
were separated into 150 flI fractions were collected using a tube piercing apparatus and
an automatic fraction collector, with 50% sucrose in MEEMG as chasing solution. 3.5
ml Scintiverse II (Fisher Scientific) were added to each fraction, and disintegrations per
minute (DPM)were counted using a Beckman LS5000TD Scintillation counter. Specific
binding is defined as the difference between total binding (incubations containing
['H]TCDD) and nonspecific binding (incubations containing [3H]TCDD plus a 200-fold
excess of TCDF).
Western Blotting
SDS-PAGE was accomplished using the NuPAGE system of pre-cast gels and
reagents: 7% tris-acetate SDS-PAGE gels, Running Buffer, Sample treatment buffer,
Antioxidant, and Sample Reducing Agent (Invitrogen, Carlsbad, CA). 100 /-Ig cytosol
protein, 12 /-Ig pSPORTmoAHR TNT product, and 30/-lg pSP64belAHR TNT product,
and 8fl1 of resuspended High Molecular Weight Marker (Sigma, S1. Louis, MO) were run
at 117 volts constant, 29-45 mamps. Gels were transferred onto 0.20 /-lID PVDF
membrane (Invitrogen) in NuPAGE Transfer Buffer (500mM Bicine, 500 mM Bis-Tris,
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20 mMEDTA, pH 7.2, plus 10% methanol and 0.1% NuPAGE Sample Antioxidant,
recipe supplied by Invitrogen). Transfer conditions were 250 mamps constant, 55-65
volts, 2 hours in Hoeffer Scientific mini transfer module.
The membrane was blocked in 1% Rad-Free Blocking Powder (Schleider and
Schuell) in tris-buffered saline (TBS: 20mM Tris, 500mM NaCl, pH 7.5). Two primary
antibodies were used. SA-21O is a rabbit polyclonal antibody directed to amino acids 1-
402 of the mouse Ahb-l allele (Biomol). BEAR2 is a rabbit polyclonal antibody directed
to amino acids 1-415 of the mouse Ahb- l allele, and it was a generous gift from Dr.
Richard Pollenz. Membranes were probed with SA-2l0 (0.6 flg/ml in blocking solution)
or Bear 2 (1 flglml in blocking solution) for1.5 hours, flipping once. Membranes washed
and then probed with secondary antibody, Goat-Anti-Rabbit Rad-Free Alkaline
Phosphatase Conjugate (Schleicher and Shuell) 1:10,000 in blocking solution. After each
antibody incubation, membranes were washed 3 times in water, and 3 times in TBS. The
membrane was then soaked in TBS, pH 9.5, then bathed in 3 m1 CSPD Ready-To-Use
(Tropix, Bedford, MA) for 5-7 minutes. Membranes were heat-sealed in plastic, and
chemiluminescence was visualized on X-OMAT film (Kodak) after exposure times of
45-minutes-5 hours. Efficiency of transfer, and size marker visualization was determined
by staining gels with Coomassie Blue.
Total RNA Isolation
Total RNA was prepared using RNAqueous-Midi Kit (Ambion, Austin, TX) with
slight modifications to the manufacturer's protocol that were required to accommodate
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the fibrous and DNA-rich nature of most of the whale tissues. Tissue powders (0.17-
0.55 g) were homogenized in 7 ml of the guanidinium isothiocyanate-based buffer with
over 20 passes with a teflon pestle, until the solution appeared clear of debris. The
temperature of the solution was kept cool during homogenization by keeping a beaker of
ice outside of the tube. The homogenate was vigorously passed through a disposable 10
ml syringe attached to an 18g needle 10 times to shear any precipitated genomic DNA.
The genomic DNA significantly increased the viscosity of the sample in the spleen,
thymus, and lymph node samples even before precipitating with ethanol. The sheared
homogenates were transferred to a 15 ml Corex tube, then spun at 7650 g (8000 rpm in
Beckman JA-20 rotor) for 15 minutes at 4'C. Using a sterile pipet and taking care to
avoid any debris at the surface as well as the pellet on the bottom, the supernatant (about
6 ml) was transferred to a sterile, disposable 50 ml conical vial. The DNA was sheared
again as described above. 6 ml of 64% ethanol was added and the solution was mixed by
inversion. The DNA was sheared again as above until there was no notable viscous
quaiity to the sample. The sample was then passed though the glass filter and washed per
the manufacturer's instructions. The RNA was eluted from the filter by passing 3
aliquots of 333fll of kit-provided Elution buffer (lOO'C) using a 3ml sterile syringe.
The sample quality was determined by running IOfll on a formaldehyde gel,
which revealed significant amounts of DNA contamination running above the 28S
ribosomal RNA fragment. Furthermore, spectrophotometric quantition revealed low
concentrations for most of the samples, spurring further concentration and purification.
300fll of the total RNA sample was concentrated to less than 100fll on a speedvac
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centrifuge equipped with a condenser. Half volumes of Lithium Chloride precipitation
solution (provided with the RNAqueous Midi kit) were added, and the samples
precipitated overnight. After spinning for 15 min at 14,000 rpm at room temperature in an
Eppendorf microcentrifuge, visible pellets were observed. The pellets were washed with
70% ethanol and resuspended in 50fll Elution Buffer (supplied with the kit). All samples
were then treated with Ix RNAsecure (Ambion) and stored at -80°C. The final quality of
the RNA was verified by visualization on an agarose-formaldehyde gel (Figure 1).
Relative RT-PCR
Sequencing beluga ~·aetin eDNA
~-actin is the non-muscle actin isoform that is highly conserved and involved in
cell motility, structure, and integrity (Vandekerckhove & Weber, 1978). Its ubiquitous
presence in cells (a "housekeeping gene") has made it an ideal candidate for control for
messenger RNA studies. It is prudent to obtain species-specific actin sequence.
Although ~-actin amino acid sequences arelOO% conserved in mammals examined so far,
the nucleotide sequences have evolved with silent mutations that occurred very recently
and at a faster rate than likely divergence times would predict (Alonso et aI., 1986). In
order to generate species-specific primers for ~-actin, the majority of a beluga ~-actin
cDNA was amplified, cloned, and sequenced. Beluga liver poly A+ mRNA was isolated
as described in Chapter 2. One /lg poly A+ RNA was reverse transcribed with random
hexamers using the GeneAmp RNA PCR Core Kit (Perkin-Elmer, Branchburg, NJ).
Degenerate ~-actin primers which amplify amino acids 18-351 of the vertebrate actin
121
gene were a gift from Hillary Morrison (Marine Biological Laboratory): 5' actin: 5'-
GAATTCTGCAGACAACGGYTCSGGTATGTGC-3', 3' actin: 5'-
CTCGAGGATCCGAAGCAYTTGCGRTGWACRAT-3'. 50 ng of each primer was
used with AmpliTaq Gold Polymerase (Perkin-Elmer) the following conditions in the
Perkin Elmer 2400 thermocycler: 95°/10:00; 94°/:15, 50°/:30 for 35 cycles, 72°/1:00.
The product was separated in a 1% agarose gel, cut out, and the DNA was extracted from
the agarose with GeneClean (Bio101). The DNA was ligated into pGEMT-Easy
(Promega, Madison, WI), transfected into JM109 high efficiency competent cells
(Promega), plated, and white colonies were selected for analysis. Three minipreps that
revealed expected size fragments upon EcoRl digest were grown up to larger scale and
the plasmid was purified by QIAprep Spin Miniprep Kit (Qiagen). The purified DNA
was sequenced from the T3 and T7 vector sites by the University of Maine Sequencing
Facility (Orono, ME). The consensus sequence was derived from forward and reverse
sequences from 3 clones that overlapped completely with no discrepancies in the
sequences. The translated sequence is shown in Figure 2, which corresponds to amino
acids 17-351, or 94% of the protein sequence.
Design of primers for RT·peR
Primers for RT-PCR were designed to avoid amplification of genomic DNA. The
complete nucleotide sequence of the beluga AHR cDNA is known (Chapter 2, Figure 2).
The intronlexon structures for the mouse AHR (Burbach et al., 1992), human AHR
(Bennett et al., 1996), and most of the fish AHR1 (Karchner et al., 1999) are known and
are identical. Therefore, it was presumed that the gene structure would be conserved in
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beluga as well. Primers were designed spanning the presumed exon junctions 6-7(ex6-
7forw (28-mer): 5'- GCTGGATAATTCATCTGGTTTTCTGGCA -3') and 8-9 (ex8-
9back (28-mer): 5'- GGCCACTCTCTCCAGTCTTAATCATCCG -3 ') to amplify a 362
base pair fragment (Figure 3). Using a relatively small product for the PCR minimizes
differences in product formation that may be a result of differential RNA degradation.
The actin primers were designed such that they would 1) amplify a product similar in size
to the AHR product, 2) have similar optimal annealing temperatures so that they could be
used in the same polymerase chain reaction run (albeit in different tubes), 3) be
discernable from the beluga product on a 2% agarose gel, and 4) span a sizable intron so
that amplification of genomic DNA would be easily detected. The ~-actin intronlexon
structure and ~-actin intron sequences are highly conserved in vertebrates (Nakajima-
Iijima et al., 1985). Primers dlactforw (20 mer: 5' -AGAGCAAGAGAGGCATCCTG
-3') and dlactback (19-mer: 5'- TAGATAGGCACGTGTGGG -3') were designed to
amplify a 322 bp fragment spanning the presumed exons 2-4 of the beluga actin sequence
(Figure 3). This region spans the largest intron among those that interrupt the coding
region of the ~-actin gene, a >400 bp intron between exons 2 and 3, thereby facilitating
identification of PCR products derived from contaminating genomic sequence.
eDNA synthesis from total RNA
Two Ilg of total RNA from 10 different tissues from 2 individual belugas, 8
tissues from each (98-1: liver, heart, lung, testis, spleen, thyroid, thymus, lymph node;
98-2: liver, heart, lung, testis, thyroid, spleen, kidney, adrenal) were reverse transcribed
into eDNA using Ornniscript Reverse Transcriptase (Qiagen) with random hexamers
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(Perkin-Elmer) in the presence of 12 units Rnasin (Promega). Another set of reactions
(one sample from each 98-1 tissue, plus kidney and adrenal from 98-2) was prepared
without the reverse transcriptase to serve as a control for PCR products derived from
genomic DNA.
Determination of optimized conditions for relative RT-peR
Initial screen. In order to determine which tissue(s) express AHR, an initial
screen of the cDNA was carried out with the actin and AHR primers under the following
conditions: 2mM MgCI, 1/lM final primer concentration with Taq gold PCR system
(Perkin Elmer) 95°/10:00; 95'/:15, 60°/:30 (35 cycles); 72°/7:00 in a Thermocycler 9700
(Perkin Elmer). A band of expected size was observed in all tissues, but because the liver
was among the tissues with the highest apparent expression levels, we carried out
subsequent optimization steps on liver cDNA from both animals and tested cDNA
detection levels using 98-1 liver cDNA.
Cycle optimization. To determine what cycles are within the linear range of
detection for transcripts, 100fll reactions were set up as described above, using beluga
liver cDNA from 98-1 and 98-2, 4 fll cDNA per 100 fll PCR. Aliquots were taken from
the tube during the annealing step of cycles 21, 24, 26, and 29 for AHR, and 20, 22, 25,
28,29,31 for l3-actin. Figure 3 shows that the upper limit of the linear range for both
AHR and actin detection in liver for both individuals is between 29 and 32 cycles (Figure
4a). 28 cycles was chosen for further experimentation. By choosing a cycle near the
upper limit of the linear range for a tissue expressing high amounts of AHR message, it
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was reasoned that it would increase the likelihood that all tissues, including those with
less AHR message, will fall within the linear range of optical density.
eDNA test. To ensure that the chosen cycle number of 28 would allow detection
of variable amounts of transcript, the liver cDNA from beluga 98-1 was used in a dilution
series that varied 8-fold (l J.!l-8J.!l). Figure 4b shows that, as expected based on the
choice of cycle number, not much resolution is possible above 41.illiver cDNA.
However, signal from AHR template is linear over at least 4-fold range (1-4 J.!l cDNA).
Actin was apparently linear over only a 2-fold range, though no points were taken
between 2 and 4 J.!l cDNA. Nevertheless, this was deemed acceptable, since actin
message was expected to vary much less than AHR message.
Relative RT-PCR from multiple tissues
Complementary DNA from all tissues was used in 25 J.!l PCR reactions with the
following conditions: 2mM MgCl, IJ.lM final primer concentration with AmpliTaqGold
PCR system (Perkin Elmer) 95°/10:00; 9SO/:15, 60°/:30 (28 cycles); 7n7:00 in a
Thermocycler 9700 (Perkin Elmer). Control cDNA reactions (minus RT) were performed
under the same conditions. 10 J.!l of each reaction was separated on a 2% agarose gel,
then soaked in 0.5% Ethidium bromide solution for 1 hour. The stained gel was
visualized using ChemiImager 4000 Low Light Imaging System (Alpha Innotech Corp.).
Bands were quantified using the accompanying SpotDenso densitometry software.
125
RT·PCR of full length AHR from beluga tissues
1 fll cDNA was amplified using Hind3nat and XBA-UTR primers that amplify
the full-length beluga AHR using Touchdown PCR as previously described (Chapter 2).
RESULTS
Detection of specific TCDD binding in tissue cytosols
Sucrose density gradient centrifugation was used to compare the ability of
cytosols prepared from various tissues to specifically bind [3Hl-TCDD. A clear peak of
specific binding (7 fmol/mg) was detected in fractions 11-19 of liver cytosol from beluga
98-1( Figure 5 panel A). This peak shares the same sedimentation coefficient (9.5 S) as
the in vitro expressed belAHR and mouse liver cytosol (Chapter 2, Figure 5). The
experiment was repeated for other tissues collected from the 1998 belugas: 98-1 heart,
lung, spleen, thymus, and lymph node (Figure 5 panels B-F) and 98-2 liver, lung, and
spleen (Figure 5, panels H-J). Small peaks of specific binding were detected in 98-1 lung
and spleen (3.3, 3.7 fmol/mg, respectively). Very small specific binding peaks were
observed in 98-1 heart, and thymus, (1.5, and 0.87 fmol/mg respectively). No specific
binding was evident in the 98-2 samples. In each extrahepatic tissue, the detectable
binding very low relative to the positive control (Figure 5, panel G; Table 1).
The peaks for the [14e] -labeled 3.6 S catalase and 11.3 S ovalbumin, standards
were detected in fractions 4-6 and 15-17, respectively. This indicated good consistency
between experiments and between gradients within experiments. The peaks of
['H1TCDD specific binding between the positive control, liver, and lung samples were all
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detected at 9.5 S. The very small peaks detected in heart, spleen, and thymus were
detected at lIS, indicating that the specific binding, if real, could have a slightly higher
sedimentation coefficient than the complex detected in liver and lung.
Immunodetection of AHR in tissue cytosols.
Western blotting was used to assess levels of cytosolic AHR in 5 individual
beluga sampled in 1998 and 1997. SA-21O is a commercially-available polyclonal
antibody against the N-terminal402 amino acids of the mouse AHR b-l allele (Figure 6).
It is known to detect AHR in mouse and rat liver, and does not cross-react with ARNT.
In Chapter 2 we showed that SA-21O cross-reacts with beluga AHR (107 kDa) by
showing that it recognized the [35]S-labeled protein band that resulted from TNT
expression of pSP64beIAHR. In the present experiments, while detecting single bands
of the expected size for the belAHR and moAHR TNT products (107 kDa and 95 kDa,
respectively) , SA-2l0 detected more than one band in cytosol from almost every
extrahepatic tissue examined (Figure 6a). For the 98-1 cytosols, a band the same size as
the in vitro expressed beluga liver AHR (107 kDa) was observed in all tissues except
heart (Figure 7). In the order of decreasing prominence, this band was observed in lung,
lymph node, spleen, thymus, liver, testis, and thyroid. No 107 kDa band was detected in
heart. However, in spleen, thymus, and lymph node, a very prominent band was also
detected that appeared to be slightly smaller than the moAHR «95 kDa). This band was
also observed in lung, but was much less prominent. The only visible band in 98-1 heart
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cytosol was slightly smaller still « 90 kDa). A band of this apparent size was also
observed in the liver.
The pattern of immunodetected bands in the second beluga sampled in 1998 (98-
2) was fairly different from that observed for the first animal. In the 98-2 samples, no
107 kDa (beIAHR-sized) bands were outstanding, and the only band of belAHR size was
detected in the lung only after prolonged exposure. The most prominent band among all
of the 98-2 samples was a band in spleen that corresponded to the smaller, more
prominent band detected in 98-1 spleen. Note that thymus and lymph node were not
available in the 98-2 samples. The single 98-1 heart band that was smaller than moAHR
was also observed in the 98-2 heart cytosol. The only liver band observed in the 98-2
sample was the same size as the 98-2 heart band, which was equivalent in size to the very
minor band in the 98-1 liver. A very faint band was observed in 98-2 kidney, this protein
ran at a size in between the spleen and heart/liver bands.
The 1997 samples were presumed to be of lesser quality than the 1998 samples
because the time between death and tissue sampling was several hours longer. Therefore,
it was not necessarily expected that the findings would match the 98 sample set because
of possible sample degradation. The bands will be described relative to the bands
detected in the 98 samples. The 97 western blots with SA-21O are shown in Figures 8
and 9. Figure 8 shows the unmanipulated image with the TNT-expressed mouse and
beluga AHRs on each as a size reference. Figure 9 is an alternative view of Figure 8 with
the 3 beluga tissues sets separated for ease of comparison between animals and tissues,
and all relative sizes were maintained during the image adjustment. In the 97 animals,
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the only band that was the same size as the in vitro expressed belAHR was detected in 2
of 4 lymph nodes sampled. The smaller of the two spleen bands was detected in both
spleens of 97 animals for which spleens were sampled. The smaller of the 2 liver bands
was detected in all three samples. The same size band was detected in 1 of 3 kidney
samples, and all kidneys revealed a band that was slightly smaller yet. The only tissue
sampled in 97 that was not represented in the 98 samples was muscle: both muscle
cytosols revealed a band that was closest in size to the small spleen band. No band was
detected in two testes samples.
In addition to the expected 95 kDa protein detected in the moAHR TNT lysate, a
70 kDa band as well as a <30 kDa band were less prominent, but visible on all blots. The
identity of the 70 kDa peptide is might be a product of proteolysis by a very fast acting,
Ca2+-dependent protease such as that which has been characterized in the Hepa 1 cell line
and liver cytosols from the C57 mouse (Poland & Glover, 1988). Similar sized bands
are not evident in the belAHR TNT lanes.
In a further attempt to characterize the bands detected by SA-21O, we obtained a
second antibody, Bear 2, which was a gift from Dr. R. S. Pollenz. Bear 2 is also a
polyclonal antibody against the mouse AHR b-1 allele, but to the expressed N-terminal
415 amino acids of the protein (Figure 6). Figure 10 shows two Western blots of gels run
with identical selected 98-1 cytosol samples under identical conditions except that one
was probed with the SA-210 antibody (Figure lOa), and one was probed with the BEAR2
antibody (Figure lOb). By comparing the TNT-expressed belAHR in both blots, it is
evident that Bear 2 does not recognize the full length pSP64belAHR expression product
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as well as does SA-210. It is therefore not surprising that bands of equivalent size to
belAHR are extremely faint in liver and lung lanes of the Bear 2 blot, while they are very
evident in the SA-21O blot. The larger bands in spleen and thymus were not detected,
and no bands were detected in heart. Surprisingly, a very strong band was detected in
spleen. Overlaying the 2 exposures revealed that the spleen band detected by BEAR2 is
smaller than the bands detected by SA-21O in spleen, thymus and lymph node (Figure
11). All other faint bands detected by BEAR2 correspond to the bands of expected size
detected by SA-210. This suggests that the bands recognized by both antibodies are
AHR, or both antibodies are capable of recognizing the same non-specific protein.
A possible explanation for the multiple bands observed in samples probed with
SA-21O is that this antibody is recognizing proteins that are related to the AHR. The
AHR repressor is a recently discovered protein that is a member of the bHLH-PAS
protein family that shares homology with the AHR, particularly at the N-terrninus
(Mimura et al., 1999). Figure 9 shows that SA-210 cross reacts readily with the in vitro
expressed mouse AHRR protein, which has a predicted size of 78 kDa, and an apparent
size of -84 kDa. Intriguingly, this is similar in size to the -90 kDa bands detected in
heart and liver of beluga 98-1 and 98-2, and the smallest band (-82 kDa) detected in 98-1
liver. In contrast, BEAR2 detects mouse AHRR only weakly. Neither antibody detects
humanARNT.
Curiously, a less intense but readily visible band of 95 kDa was recognized by
SA-210 in the mo AHRR and huARNT TNT lanes (Figure 10). In previous
experiments, this band has been observed in unprogrammed lysate, but only after
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overexposure of the blot. Since the band was detected in rabbit cell lysate using a
polyclonal primary antibody and anti-rabbit secondary antibody, in the past we have
regarded it as non-specific. However, with the batch of TNT lysate used in this
experiment, this 95 kDa band is obvious and is the same size as the smaller bands in
liver, lung, spleen, thymus, and lymph node. The cloned rabbit AHR when expressed in a
rabbit reticulocyte lysate in the presence of [35]S methionine has an apparent size of 94
kDa (Takahashi et al., 1996), the same size as the band observed here. Further, when a
gel with TNT lysate, liver and lung cytosol was stained with Coomassie blue instead of
transferred to a membrane, there were no outstanding bands in the size range in question
that might implicate non-specific interactions from overloaded protein (data not shown).
Therefore, the band detected in the TNT lysate might be AHR, as discussed below.
Detection of AHR transcripts from total RNA from various tissues
Relative RT-PCR was used to detect AHR transcripts in several tissues of beluga
sampled in 1998. The AHR mRNA expression was normalized to ~-actin and compared
to results obtained by velocity sedimentation and western blotting, as well as to results
obtained by other investigators in other species. Figure 12 shows results of a
representative experiment in which AHR and ~-actin transcripts were measured using the
optimized conditions arrived at as described in the Methods: 28 cycles using 4 J.!l cDNA
per 100 J.!l reaction. Beluga AHR transcripts are clearly expressed in all tissues.
Normalizing to actin and repeating the experiment did not reveal any differences in
tissue-specific AHR expression that were observed consistently between experiments or
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between animals (Figure 13). However, the expression levels in liver were consistently
no less than 90% of the maximum. Because expression levels so close to liver were not
expected, and because liver was used to optimize the assay, the experiment was repeated
with fewer cycles to see if the conditions might show greater resolution of relative
expression among tissues. When 25 cycles was used, liver clearly expressed the highest
levels of AHR in both animals. When normalized to the maximum amount of expression,
25 cycles exposes lower relative expression in the heart and testis of both animals, and
lower expression in spleen of 98-2, but not in 98-1. Figure 14 shows that no bands were
observed in tubes where reverse transcriptase was not present, indicating that all PCR
bands are derived from RNA message, and not contaminating genomic DNA. Taken
together, the overall expression trends indicate that the tissues exhibiting the highest
AHR mRNA expression are liver, lung, and kidney, tissues expressing high levels are
thyroid, spleen, thymus, lymph node, and adrenal, and relatively low amounts of AHR
mRNA was detected in heart and testis.
Detection of full length belAHR transcripts in tissues
As a means of probing for transcripts of alternative lengths, and to support further the
relative RT-PCR results, the full-length AHR was amplified from one sample of each
tissue from the 1998 belugas. The primers were the same primers derived from 5' and 3'
RACE products that successfully amplified the full AHR coding region from beluga
liver (Chapter 2). A product of expected size (2.5 kb) was detected in all tissues tested.
Again, liver produced the most prominent band, which had an optical density 2-fold
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greater than that from lymph node. Lung, spleen, thymus, and adrenal were all amplified
to similar degrees, and only slightly less signal was observed in heart, testis, thyroid and
kidney. The conditions for the full-length amplification were not optimized for
comparisons of relative expression.
DISCUSSION
In order to further characterize the cetacean AHR and understand the potential for
AHR-dependent toxic effects in cetaceans, the tissue-specific expression of the AHR was
examined in the beluga. Three methods were employed to quantitate AHR, and each
measured different properties of the AHR: sucrose gradients measured the AHR ligand
binding, western blotting measured protein occurrence in the cytosol, and RT-PCR
measured AHR transcription. These results show that 1) AHR mRNA is expressed in all
tissues examined, 2) AHR protein is prevalent in lung, liver, and lymphoid organs, but is
not as prevalent in heart, testis, and adrenal, and 3) the minimal detection of AHR
binding by extrahepatic tissues could be indicative of low AHR expression in these
tissues, but in light of the AHR mRNA and AHR protein data, inadequate sample quality
is a more likely reason. Taken together, these results are consistent with tissue-specific
pathologies observed in cetaceans and suggest that the AHR and its ligands could play an
important role in cetacean disease.
AHR message is expressed in many beluga tissues
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RT-PCR was used to assess the relative expression of AHR in eight tissues from 2
individual adult male belugas. The relative RT-PCR protocol, which was shown to have
a linear range of detection of at least a 4 fold difference in cDNA (Figure 4b), detected
reverse transcribed mRNA in all tissues examined (Figure 12). This is consistent with
results of other investigators who have measured AHR mRNA expression in human,
mice, and rats (Carver et aI., 1994; Dolwick et al., 1993; Li et aI., 1994). The beluga
tissues with the highest expression relative to actin were liver, lung, and kidney, followed
by spleen, thymus, lymph node and thyroid. (Table 1). Table 2 summarizes results of
studies in other mammals and displays the relative abundance of AHR detected in each
tissue, as well as the species and method used. For the AHR RNA detection methods
listed, all investigators observed very high expression of AHR in the lung. Although
substantial expression in the lung was seen here, the highest levels of expression were
consistently observed in the liver (Figures 12-14). The patterns of beluga RNA
expression follow more closely the pattern of the rat, with high RNA expression observed
in liver, thymus, and kidney (Carver et al., 1994). These trends differed from the patterns
for human, for which high AHR mRNA expression was found in heart and placenta
(Dolwick et aI., 1993).
The goal for these experiments was to assess patterns of tissue-specific expression
in beluga, and observe where AHR mRNA tissue-expression patterns might differ from
those of other mammalian species. Such differences were not observed. Thus, the
observation that AHR message is readily detected in all tissues examined from 2 healthy
beluga suggests that AHR protein may normally be expressed in all tissues of beluga.
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AHR protein is immunodetected in many tissues
In beluga 98-1, a band of -107 kDa was observed in almost all tissues. The same
sized band was detected in the lung of 98-2. This was the same size as the in vitro
expressed beluga AHR that was confirmed to be AHR in previous chapters. Therefore,
we conclude that the 107 kDa band is beluga cytosols is the AHR. The relative
expression pattern of this AHR is lung> liver=spleen=thymus=lymph node » testis =
thyroid; no protein of this size was immunodetected in the heart. However, smaller bands
(-80-95 kDa) were detected in the liver, heart, lung, spleen, thymus, and lymph node of
98-1, and liver, heart, spleen, kidney, and adrenal gland of 98-2. Non-specific binding is
always a possibility when polyclonal antibodies are used, since a number of different
epitopes may be recognized, thus increasing the odds for non-specific interactions.
Interpretation was further hampered by the limited ability of BEAR2 to detect beluga
AHR. In light of what is known about the physiochemical properties, regulation, and
evolution of the mammalian AHR, the presence of the smaller immunodetected bands
could reflect: 1) products of proteolysis during autolysis, 2) post-translational
modification of AHR, 3) an AHR-related protein, 4) an alternative splice product of the
AHR, or 5) an alternative AHR allele or gene.
Possible interpretations for multiple bands
Proteolysis occurs in tissues via targeted, necrotic, or autolytic pathways.
Proteolysis as a result of autolysis is an especially important concern for these beluga
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samples because it was logistically impossible to sample the tissues immediately after
death. Most AHR studies have been conducted in laboratory rodents that can be
conveniently sampled immediately post-mortem. However, even in rapidly preserved
samples the AHR is well known to be very sensitive to post-mortem degradation. For
example, the mouse AHR (Ahh.' allele) is degraded by a calcium-dependent protease that
generates a 70 kDa peptide that retains its binding properties (poland & Glover, 1988).
The degradation was so rapid that only perfusion of the mouse liver with EDTA-
containing buffer before homogenization could minimize its occurrence. A similar-sized
band was observed here in a 90 minute mouse AHR TNT reaction, although whether this
band is a proteolytic product was not tested. (Figures 8,9,10). Further, it has been shown
that other mouse alleles (such as the mouse AHR b-2, b-3 and d alleles are even more
labile than the b-l allele in vitro (Poland & Glover, 1990; Poland et al., 1994). In another
study, these same authors also note "two to three other peptides" in mouse liver cytosol
with molecular masses between 70 and 95 kDa which also bind to ligand specificially
(Poland et al., 1986). In a study that monitored the disappearance of AHR after nuclear
translocation, the investigators observed bands of slightly smaller molecular weight than
the AHR in rat spleen, thymus, and lung (Pollenz et aI., 1998). The authors described
these bands as non-specific. However, since the intensity of the smaller bands appear to
correlate with the intensity of the AHR band, it seems possible that these bands are
proteolytic products of an N or C-terrninal amino peptidase that does not affect critical
epitopes. Huska et al. (1998) found multiple bands, including a very prominent 50 kDa
band, that were immunodetected during the developmental stages of mouse mammary
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epithelium. These authors interpreted these as proteolytic fragements despite their use of
protease inhibitors in buffers (Hushka et al., 1998). Thus, the beluga AHR as well may
be especially sensitive to proteolysis.
The reason for the rapid autolysis of AHR may be related to its mechanism of
regulation. A growing number of studies are revealing that targeted proteolysis of the
AHR is important for ligand-dependent regulation of the AHR (Davarinos & Pollenz,
1999; Lees & Whitelaw, 1999; Pollenz, 1996; Pollenz et al., 1998; Roberts & Whitelaw,
1999). After translocation to the nucleus and gene induction, the AHR is exported back
to the cytosol, ubiquinated, and degraded by a proteosome complex (Roberts &
Whitelaw, 1999). Therefore, the fragments observed in cytosols of laboratory rodents
and beluga may reflect breakdown of the proteosome complex during post mortem
autolysis, which could account for the rapid, yet incomplete AHR degradation.
The degree of proteolysis should increase with time lapsed between death and
sampling. The disappearance of the belAHR 107 kDa band and smaller bands seems to
reflect this trend: as the post-mortem sampling delay increases as represented by 98-1
(freshest, about 60-90 min post-portem time to sampling), 98-2 (about 3-4 hours) ,97-1
(4-5 hours), 97-2 (5-6 hours), and 97-3 (6-8 hours, longest post mortem-sampling delay),
the larger bands in each respective tissue cytosol disappear (Figures 7-8).
The BEAR2 and SA-210 antibodies dectected major bands in spleen that were
distinct in size. One of the bands recognized by SA-210 was the full-length AHR. The
single small band recognized in spleen by each antibody is distinct in size from one
another. This is intriguing, particularly since Bear 2 does not recognize the full-length
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beluga AHR well relative to the mouse AHR. To presume that either band is non-
specific binding seems improbable. One interpretation is that different proteolytic
fragments could differ in their recognition by different antibodies, and particularly those
raised against truncated proteins (instead of full-length proteins). If proteolysis exposes
an epitope that is conserved among species, it is conceivable (though improbable) that a
peptide fragment of a whale AHR could be detected more easily than the full length
whale AHR by an antibody raised against mouse AHR. A satisfactory interpretation for
these results is not forthcoming.
The second possibility for the multiple bands detected in the western is that the
prominent -95 kDa is a product of post-translational modification. The TNT reactions
used for the mouse AHRR and the human ARNT proteins (Figures 7-11) are
accomplished in lysate that is derived from rabbit reticulocytes, presumably harvested
from the blood or spleen, a secondary site of hematopoeisis in rodents. Reticulocytes are
immature erythrocytes that have recently expelled a nucleus and are poised to lose
mitochondria and ribosomes, at which point they are mature erythrocytes (Kuby, 1998).
Studies with chimeric AHR knockout mice show that AHR-dependent TCDD toxicity
occurs in hematopoetic precursor cells in bone marrow (Staples et al., 1998). A high
proportion of the spleen, thymus, and lymph node tissues are lymphocytes. Since these
and reticulocytes are derived from a common precursor cell, the detected band in the
TNT may be related to the second, smaller band detected in beluga spleen, thymus, and
lymph node. The cloned rabbit AHR when expressed in a rabbit reticulocyte lysate in the
presence of [35S]-methionine has an apparent size of 94 kDa (Takahashi et al., 1996), the
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same size as the band observed here. The rabbit AHR is 847 amino acids in length,
which is very similar to the beluga AHR (845 aa) and the human AHR (848 aa). The
predicted sizes of these proteins are 96.1, 95.5, and 94.4 kDa for human, beluga, and
rabbit AHRs, respectively. The sizes of the AHRs as determined by photoaffinity
labeling is -llO kDa for both human HeLa cytosol and the TNT-expressed huAHR clone
(Dolwick et al., 1993), -110 kDa for beluga cytosolic liver AHR (Hahn et al., 1994), and
104 kDa for rabbit cytosolic liver AHR (Poland & Glover, 1987). In contrast, using the
TNT expression system, apparent sizes of human and beluga AHRs are equal, -107 kDa
(human AHR data not shown) and the rabbit AHR is 94 kDa (Takahashi et al., 1996). It
is possible that some post-translational modification may be occurring for the rabbit in
the conspecific rabbit reticulocyte lysate environment that is not occuring with the in
vitro expressed beluga and human AHRs, but is occurring in the beluga cytosols,
particularly the lymphatic tissue cytosols. Not much is known about post-translational
modification of the AHR, and it is interesting to consider the possibility that the 107 kDa
and 95 kDa bands represent latent and activated forms that contribute to tissue-specific
susceptibility to AHR ligands. This is pure speculation, however, since deviations from
predicted molecular weights are common, and there is no evidence of post-translational
modification of AHR size in any other system examined thus far.
Another possibility for the identity of the alternate bands detected in the western
blots is that they are AHR-related proteins that are cross-reacting with the SA-210
antibody. The antibody SA-21O recognizes belAHR better than does BEAR2 (Figure
10), which may be because the epitopes recognized by SA-210 are more highly
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conserved than those of BEAR2. Because the N-terminus of the AHR includes the
conserved bHLH and PAS domains (Figure 6), it seemed possible that SA-2l0 might be
recognizing epitopes that are conserved among related proteins as they are conserved
across species. To test this, we included an in vitro expressed mouse AHR repressor, and
an in vitro expressed human ARNT protein on gels that were blotted with both
antibodies.
AHRR is a newly discovered PAS protein that is induced by AHR activation and
blocks AHR binding with ARNT. The potential for 3- methylcholanthrene (3MC)
induction is tissue-specific, with the highest AHRR mRNA levels detected in mouse
heart and lung (Mimura et al., 1999). The AHR repressor shares high sequence identity
with the moAHR, as high as 81 % in the bHLH domain and 60% in the PAS-A domain.
The PAS-B characteristics are absent, and the C-terminus shares only 19% amino acid
identity with AHR (Mimura et al., 1999). ARNT is the nuclear dimerization partner for
the AHR, which shares about 19% amino acid identity with AHR in the bHLH-PAS
domain (Gu et al., 2000). We noted earlier that the SA-2l0 antibody does not cross-react
with rodent ARNT, and as expected, SA-21O did not reveal a human ARNT band (Figure
10). This suggests that none of the cross-reacting bands are beluga ARNT. However,
SA-21O (but not BEAR2) detected the mouse AHR repressor (AHRR). Intriguingly, the
only band detected in heart and the smallest band detected in liver are similar in size to
the mouse AHRR. Despite this interesting possibility, we must interpret with caution,
since we know nothing about the existence, size structure, or regulation of a beluga
AHRR.
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Another possible reason for the multiple bands is the occurrence of splice
variants. Many splice variants have been identified in AHR and in other PAS proteins.
We screened for particular types of splice variants by using the primers designed to
amplify the full length AHR in beluga liver. A product that corresponded to the complete
beluga AHR coding region was amplified in all tissue types (Figure 13). This allowed us
to rule out the occurrence of any splice variant that utilizes the same start and stop
codons, unless the splicing event results in a transcript of exactly the same size. This
includes most types of splice variants, including an optional exon, an optional intron,
mutually exclusive exons and internal spice sites, since in most cases these splicing
events produce a final transcript of a different size. Examples of alternate splicing
events have been described for AHRs in several species. For example, a rare variant in
the Sprague-Dawley rat has a 699 bp deletion spanning exons 5-8 (Carver et al., 1994).
The TCDD-resistant HanlWistar rat has a mutation in a splice site that causes the random
use of cryptic splice sites. This results in 3 discernable transcripts, 2 with insertions and
1 with a deletion (Pohjanvirta et aI., 1998). Similar splicing events in beluga would have
been detected using these primers, since the original stop codon (though not used in the
translated products in the HIW rat) was still present in the transcripts.
This full-length PCR test could not, however, detect splice products that arise
from an alternative use of 5' start sites or 3' termini, for which there are many examples
among PAS proteins. The only AHR example is the Fundulus AHRII3, which exhibits a
rare alternate 3'coding region with a unique stop codon and UTR (Karchner et al., 1999).
Similarly, apparent alternate splice products of rainbow trout ARNT (rtARNTa and
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rtARNTb) have unique carboxy-termini (Pollenz et al., 1996). Hif-la undergoes splicing
to accomplish two dominant forms with alternative exons 1 (Wenger et aI., 1997). When
such products are the result of regulated alternative splicing, then different products often
have tissue-specific or condition-specific patterns of mRNA expression. When the
alternative splicing is consitutive, both products are expressed, but may be regulated at
the protein level (Alberts et al., 1994). These examples and others suggest that
constitutive and regulated alternative use of 5' and 3' ends are a common theme in PAS
proteins. Therefore we cannot confirm nor rule out the possibility that the bands detected
by western blotting arise from alternative splicing events without further study.
Another interesting possibility is that the SA-2l0 antibody is recognizing products
from different genes or alleles. There are many examples of strain-specific alleles as
well as multiple gene isoforms in the PAS protein family. For example, there are at least
four, well-characterized AHR alleles in various mouse strains that represent 2 different
sized proteins (Poland et al., 1994). Two alleles have been well characterized in rat
strains, and these also are very different in size (Pohjanvirta et al., 1999; Poland &
Glover, 1987). At least 3 alleles occur in humans, though all result in single amino acid
changes (1 in exon 2 and 2 in exon 10) and do not appear to change the protein length
(Kawajiri et al., 1995; Smart & Daly, 2000). Most PAS proteins to date are shown to
exist as paralog groups (e.g. SIMI and SIM2). Paralog groups are generally believed to
arise from a gene duplication event, though alternative scenarios have been suggested
(Hahn et aI., 1997). In the case of the AHR, both members of the paralog group (AHR1
and AHR2) have been identified in the mummichug (Karchner et al., 1999), while the
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non-mammal-like isoform (AHR2) has been found in zebrafish (Tanguay et al., 1999)
and rainbow trout (Abnet et al., 1999). The second isoform, which appears to be the
more ubiquitous form in fish, has not been identified in mammals despite extensive
effort. The observation that two predominant bands were detected in lung, spleen,
thymus, lymph node, and possibly liver, is intriguing in this light. The validity of these
speculations may be clarified with further study.
Lack ofsubstantial TCDD Binding in extrahepatic tissues
Velocity sedimentation on sucrose gradients was not particularly useful for
comparing AHR in these beluga tissues. The low or undetectable specific binding in
extrahepatic tissues could be because I) the AHR protein was degraded, 2) the AHR
protein has minimal or no binding function, and/or 3) the concentration of AHR was too
low to detect in these samples. These possibilities are not mutually exclusive. From the
western blot data, we favor the interpretation that proteolysis has, at least in part, affected
the detectable AHR protein pool and these effects become more significant as the post-
mortem time before sampling increases. The observation that minim~1 to no specific ['H]-
TCDD binding was observed in tissues other than the 98-1 liver is in accordance with this
interpretation, since it was the very first tissue sampled from this animal. Alternatively,
some or all of the AHR protein in certain cytosols may be non-functional. An example of
an AHR with compromised binding function is the Ahd allele. After no specific binding
was detected for any tissue in an Ahd/Ahdmouse (Mason & Okey, 1982), it was later
shown that this was because the product of the Ahd protein has a lower binding affinity
compared to the Ahb alleles (Poland et al., 1994). Alternatively, the pool of AHR that
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binds [3H]-TCDD may be a subset of the total cytosolic AHR, and these ratios could be
post-translationally regulated and tissue-specific. For example, phosphorylation is
involved at several points along the AHR signal transduction pathway. Protein kinase C
activity is required for transcriptional activation of the AHR-ARNT-DRE complex
(Carrier et al., 1992; Long et aI., 1998). Phosphorylation of the AHR occurs upon TCDD
binding, suggesting a requirement for phosphorylation in AHR activation (Enan &
Matsumura, 1995). Gradin et al. demonstrated that blocking a tyrosine phosphorylation
site within the ligand-binding domain of the AHR inhibited ligand-activated dissociation
of Hsp90, but apparently not ligand binding (Gradin et al., 1994). A phosphorylation
requirement has not been demonstrated for ligand binding, but it remains a possibility and
a reminder of the myriad of modifications that occur in the cell's native environment. If
modification that affects TCDn binding does occur in beluga tissues, this would explain
the ability to detect AHR by immunoblot despite very low levels of specific binding. At
the same time, the fact that specific binding was observed in lung, heart, thymus, and
spleen strengthens the argument that the bands detected by western blot for those
respective tissues are AHR, and a functional AHR pool exists in these tissues. This is
particularly interesting for the heart; since no band of 107 kDa was detected, this suggests
that the -90 kDa band not only may be AHR, but may be TCDD-binding AHR.
To summarize, the most critical data presented in this chapter is the western blot
of beluga 98-1 tissues. With support from immunoblots of four other belugas, relative
RT-PCR, and ,specific binding data, we conclude that lymphoid tissues (thymus, spleen,
and lymph node) and lung express the highest levels of AHR protein. AHR is expressed
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in moderate to high amounts in liver, and kidney, and low amounts are expressed in
testis, thyroid and heart. Given the data in hand, the most likely explanations for the
detection of the 107 and 95 kDa proteins in certain cytosols are either proteolysis during
early autolysis, or post-translational modification. The evidence from these five beluga
shows that the most likely targets for PHAH action via the AHR are the lymphoid organs,
lung, liver, and kidney.
Conclusions
These studies show that the AHR, a factor that is necessary for the toxicity of
planar halogenated aromatic hydrocarbons, is ubiquitously expressed at the level of
mRNA. Protein levels are relatively high in the lymphoid organs, liver, and lung,
implying that these may be targets for toxicity of PHAH and other AHR ligands. These
results are consistent with a role for the AHR in apparent immunosuppression in
cetaceans with high body burdens of PHAH. Furthermore, relating in vitro and
molecular data to field observations is a productive approach for assessing the sensitivity
of a species for which dosing studies are logistically and ethically impossible.
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Figure 1. Quality control check for total RNA isolated from various
tissues from two individual belugas, 98·1 and 98-2. 5 Jlg RNA (as
measured by OD26,,J was loaded in each lane and resolved with electrophoresis
on an agarose-formaldehyde gel.
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Figure 2. Sequence and translation of partial beluga ~-actineDNA. Beluga
liver mRNA was reverse transcribed to cDNA and amplified using degenerate
primers designed to vertebrate fI-actin. Probable exon junctions based on
manunalian fI-actins are numbered. Nucleotide numbers correspond to the numbers
of the partial sequence, and residue numbers correspond to 375 amino acid
mammalian actin sequence.
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Figure 3. Beluga ~.actin primer design. (A) Schematic of full length AHR and ~­
actin cDNAs. Numbers refer to exons deduced from vertebrate sequences, Dark
boxes above represent location of target sequences (not to scale)_ Labeled lines above
primers indicate predicted product size. (8) Conservation of nucleotides within
primer region for select mammals.
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Figure 4. Parameter optimization for relative RT-PCR with beluga AHR
and l3-actin. (A) AHR and actin cycle number optimization. PCR was run witb
98-1 and 98-2 beluga liver cDNA derived from total RNA. Reaction witb AHR
primers were run for 21,24,26,29, and 35 cycles, and the reaction with l3-actin
was run for 20,22,25,28,31,32, and 35 cycles. 10 III was electrophoresed on a
2% agarose gel and stained witb ethidium bromide. Visualization and
densitometry was done using the ChemImager 4000 system. The Y axis
represents optical density units measured, minus background. (B) cDNA dilution
test. 98-1 liver cDNA was diluted in water up to 8-fold and run with 28 cycles
with AHR and l3-actin primers in separate tubes but in the same machine run. Y-
axis represents OD units from 10 J.!l as in A.
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Figure 5. Specific 3H.TCDD binding in 98·1 and 98·2 belugas. Cytosols
were incubated with 3H-TCDD, plus DMSO or 200-fold excess TCDF,
applied to a sucrose gradient and sedimented. Solid diamonds represent total
binding disintegrations per minute (DPM) per fraction, hollow diamonds are
non-specific binding DPMlfraction. Small triangles indicate peak of 14C_
labeled 3.6 S and 11.3 S protein size standards. Specific binding (fmol/mg)
and sedimentation coefficients are indicated. Panels (A) through (F) show
98-1 tissue cytosols. Panels (H) through (1) show binding in tissue cytosols
from beluga 98-2. Panel (G) shows binding of TNT expressed beluga AHR,
used as a positive control run for samples in panels (D) through (1).
153
154
o
I
100 200
I I
300 400
I I
500 600
I I
700
I
800
I
900
I
bHlH PAS domain Q-rich
~c1!l!:t1i!'i!i B ~l' ~---,'---- ~
bHlH PAS domain Q-rich
~~,,'0'" B ,:&, ~1I-, ..J:~I
bHlH PAS domain
belAHR
845aa
95.5KDa
moAHR
799aa
89.6KDa
SA-210 antigen
402aa
45.7KDa
bHlH
bHlH
PAS domain
PAS domain
BEAR2 antigen
415aa
47.5KDa
moAHRR
70188
77.8KDa
bHlH PAS domain Q-rich
~,--_----,~===n huARNT790aa86.6KDa
Figure 6. Structures of AHR aud related proteins and antigens. General structure
and major domains of proteins that were in vitro expressed and used in Western blots
as indicated in the text. The protein fragments that were used by others to generate
polyc1onal antibodies SA-210 and BEAR2 are also shown.
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Figure 7. Western blots of 1998 beluga tissue cytosols. 100 flg cytosol protein
was separated on a 7% tris acetate gel, transferred to PVDP membrane and probed
with SA-2l0 rabbit-anti-mouse AHR polyclonal antibody (Biomol). Alkaline
phosphatase conjugated goat anti-rabbit (S&S) was the secondary antibody, and
visualization was with Tropix CSPD (Tropix) and exposure to Kodak X-Omat
film. The plasmids pSP64beiAHR and pSPORTmoAHR were used in a rabbit
reticulocyte lysate transcription/translation system (non-radioactive) to serve as
positive controls and for size comparisons. (A) shows cytosols from beluga 98-1,
and (B) shows cytosols from 98-2.
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Figure 8. Western blots of 1997 beluga tissue cytosols. Tissue cytosols were
run as in Figure 7, but with cytosols prepared from belugas 97"1, 97-2, and 97-3
as indicated.
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Figure 9. Western blots of 1997 beluga tissue cytosols (alternative view).
Alternative view of Figure 8, with tissues shown in columns for ease of tissue and
animal comparison. Relative positions were maintained during manipulation of
the image. (A) 97-1 cytosols. (B) 97-2 cytosols. C. 97-3 cytosols.
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Figure 10. Western blots of 98-1 beluga tissues with SA-10 and BEAR2.
Select cytosols from beluga 98-1, plus TNT products of plasmids containing
beluga AHR, mouse AHR, mouse AHR repressor, and human ARNT were probed
with (A) SA-21O as in Figure 7, or (B) with the same conditions but with BEAR2
primary antibody.
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Figure 11. Overlay of Western blots from Figure 10. The films from Figure 10
were overlayed to show that the bands detected with BEAR2 are the same as those
detected with SA-21O, with the exception of the -90 kDa band in spleen detected by
BEARZ (indicated by arrow).
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Figure 12. Relative AHR expression patterns in 98-1 and 98-2 tissues using
relative RT-peR. Total RNA was reverse transcribed to cDNA and PCR was
perfonned under optimized conditions as determined in the Methods: 28 cycles
with 4 fll cDNA/IOO fll reaction. (A) 10 fll of the PCR was separated on a 2%
agarose gel, then stained with ethidium bromide. (B) Optical density was
determined for each band, background was subtracted, then signal from each
tissue was plotted as a ratio of AHR/actin.
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Figure 13. Summary of AHR mRNA expression as determined by relative
RT·peR. Four experiments are summarized. For ease of comparison, each tissue
is plotted as a fraction of the tissue that showed the maximum AHRJactin OD
ratio for each animal. A. Three experiments were carried out using 28 cycles, as
in Figure 12. In all trials with 98-1, the maximum expression was in liver. For
98-2, maximal expression was observed in liver, lung, or kidney. Bars indicate
standard deviation. B. Additional experiment run under identical conditions as
in A, except 25 cycles were used, for reasons detailed in the text.
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Figure 14. RT-PCR signal does not arise from contaminating genomic DNA.
Two approaches were used to minimize signal from genomic DNA
contamination: 1) The RNA was LiCI precipitated, which excludes large DNA
and very small RNA, and 2) AHR primers were designed to span splice junctions
and actin primers were designed to exons flanking a large intron. A separate set of
cDNA, synthesis reactions were carried out without reverse transcriptase enzyme.
In two additional tubes containing liver and spleen total RNA, reverse
transcriptase was added last to serve as a positive control for the master mix and
the RNA handling. All control cDNA tubes were amplified and visualized as in
Figure 12.
170
Actin -RT AHR-RT
Liver Liver
Heart Heart
Lung Lung
Testis Testis I IQ
co
•
Spleen Spleen . ~
Thyroid Thyroid
.....
-J Thymus Thymus.....
Lymph node Lymph node
Kidney Kidney I IQco,
Adrenal Adrenal •
N
Liver (+RD Liver (+RD I IQco,
Spleen (+RT) Spleen (+RT)
~
Figure 15. Full-length AHR transcripts are detected in all tissues using RT-
peR. Full length beluga AHR transcripts were amplified using primers designed
to regions overlapping the start codon, and just downstream of the stop codon; as
described in Chapter 2. Touchdown PCR and 35 cycles were used to maximize
specificity and detection.
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Table 1. Summary of tissue specific expression data for 98 belugas. Based on 98-1
tissues plus kidney and adrenal from 98-2:
method Highest High Medium Low None
(++++) (+++) (++) (+) detected
SDG
Liver x
Heart x
Lung x
Testis
Thyroid
Spleen x
Thymus x
Lymph node x
Kidney
Adrenal
WESTERNS
Liver x
Heart x
Lung x
Testis x
Thyroid x
Spleen x
Thymus x
Lymph node x
Kidney
Adrenal
RT-PCR
Liver x
Heart x
Lung x
Testis x
Thyroid x
Spleen x
Thymus x
Lymph node x
Kidney x
Adrenal x
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Table 2. Summary of tissue-specific expression data from the literature.
Snecies Method Liver Heart Luna Testis Soleen Thvmus Kidnev
CS7BU6J SDG. +++++ - ++++ - ++ ++
mouse
CS7BU6J SDGb ++++ +++
mouse
DBA-2J SDG. - - -
- -
mouse
Guinea pig SDGb ++++ ++ +++++ ++++ ++ ++++ +++
Hamster SDGb ++++ - +++ - + + ++
SoD rat SDG. +++++ - +++++ - +++++ +
SoD rat SDGb ++++ ++++ ++++++
SoD rat HAP, ++++ +++ +++++
SoD rat Isoelectric ++++ +++++ + +++++ ++++
focusing d
Human SDG. +++1 +++
SoD rat Western f ++ +++ ++++ +++
CS7BU6 Phataaffinity/ ++++ ++ +++++ ++++ +++ ++
Immunappt.
Human Northern h ++ ++++ ++++ ++
SoD rat RPA; ++++ + +++++ + ++++ ++++
CS7BL Competitive ++ + +++++ + ++ +
mouse RT-PCRJ
Rabbit ~-1 mapping k, +++ + ++++ ++ +++
• Mason & Okey, 1982
b Gasiewicz & RUCci, 1984
, Poellinger et al., 1985
d Carlstedt-Duke, 1979
• Harper et al., .1988; Harper et aI., 1991; Manchester et aI., 1987; Roberts et aI., 1986;
Roberts et aI., 1990
f Po!Ienzetal, 1998
• Poland et aI., 1991
h Dolwick et aI., 1993
; Carver et al., 1994
j Li et aI., 1994
k Takahashi et aI., 1996
m= cell line
n== no values were reported from this paper, so this interpretation was based on the
apparent relative optical densities in Figure 4, and the authors' report that AHR was
detected in every tissue (e.g. where I could see no signal, a "+" was inserted in the table).
176
Lymphoid
Brain Muscle Placenta Intestine Prostrate Skin Pancreas (B)" cells Ovarv Adrenal
- + +
-
- - -
++ - ++ - +
++ - - - -
- - +++ -
+ + - - -
+++ +++ m +++ m +++ m
++
++ ++ ++++++ ++
+ ++
+ + +
+ + +
177
178
Chapter 5:
Summary, Conclusions and Future Directions
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Marine mammals are known to accumulate high levels of persistent contaminants
in their tissues. However, the effects of high burdens of contaminants on marine mammal
health are largely unknown. Because of ethical, legal, and logistical obstacles, direct
toxicity studies in marine mammals are usually impossible. This thesis demonstrates an
approach that circumvents these difficulties by conducting in vitro studies and examining
a protein known to be necessary for the toxicity of a class of potent environmental
contaminants, the planar halogenated aromatic hydrocarbons. Specifically, I examined
the molecular and functional properties, as well as tissue distribution of the aryl
hydrocarbon receptor from the beluga, an odontocete cetacean.
The major findings of this thesis were:
• The beluga AHR shares high sequence identity with other mammalian AHRs,
especially with the human AHR (85%)
• The beluga AHR has similar (or greater) TCDD binding affinity compared to that of
the Ahb-I mouse allele, a classic "high-affinity" mouse AHR.
• Relative potencies for AHR binding suggest that structure-binding relationships are
similar in beluga and rodents, and thus support the use of TEFs for cetaceans.
• High AHR protein expression was found in lymphoid tissues (thymus, spleen, lymph
node, liver, and lung).
The AHR from beluga liver was isolated, cloned, and sequenced. The 3.2 kb
cDNA encoded an 845 amino acid protein with a predicted size of 95.5 kDa. Overall the
beluga AHR shared 85% amino acid sequence identity with the human AHR and 75%
identity with the mouse AHR Ahb-I allele. Beluga AHR protein synthesized in a rabbit
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reticulocyte lysate system demonstrated specific, high affinity [3H]_TCDD binding. In a
charcoal-dextran binding assay with varying concentrations of ['H]-TCDD, the binding
affinity of the beluga AHR was compared to that of an AHR from a dioxin-sensitive
mouse strain (product of the Ahb-l allele) and with the human AHR. In this comparison,
the beluga AHR bound ligand with an affinity (Kd=0.43 ± 0.16) that was at least as high
as that of the mouse AHR (Kd=0.68±0.23), and significantly greater than that of the
human AHR (Kd=1.63 ± 0.64).
In order to further the characterization of the beluga AHR and begin to establish
an experimental basis for the application of Toxic Equivalency Factors to cetaceans,
competitive inhibition studies were conducted to measure binding affinities of different
structure classes of HAH. From these binding studies, relative potencies (factors that
describe potency for a compound relative to the potency of TCDD) were derived for
HAH binding to the in vitro-expressed beluga AHR. In order to again compare with a
well-characterized AHR, the high-affinity mouse Ahb-1 allele was included in all in vitro
analyses. Overall affinities of HAH for the beluga AHR were higher than were the HAH
affinities for the mouse AHR. Structure-binding relationships were very similar between
the beluga and mouse AHRs and within the different structure classes of HAH tested.
Relative potencies calculated for the coplanar HAH were correlated with Toxic
Equivalency Factors (TEFs) determined for humans and mammals. Thus, these data
support the use of rodent-derived TEFs for PCBs for cetaceans. However, since REPs
and TEFs do not correlate as well for the mono and di-ortho PCBs, and because no data
exist showing efficacy of the mono-ortho PCBs, TEFs for mono-ortho PCBs should be
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used with caution, and TEFs for di-ortho PCBs are not likely to be valid. This was the
first determination of relative potencies of any kind for a marine mammal, and the most
comprehensive set of relative potencies derived for HAH binding to in vitro mouse AHR.
To determine potential targets for AHR-mediated toxic effects in the beluga, the
tissue-specific expression of AHR was examined. Several tissues were collected from 5
male beluga from the Alaskan Arctic. Three methods were used to measure AHR
expression: 1) ligand binding in cytosols, 2) presence of immunodetectable AHR protein
in cytosols, and 3) messenger RNA expression. These studies show that the AHR is
ubiquitously expressed at the level of mRNA in the tissues examined. Protein levels are
relatively high in thymus, spleen, lymph node, liver, and lung, implying that these may be
targets for toxicity of coplanar HAH as well as other AHR ligands.
The observation that the beluga possesses a high affinity AHR, together with the
demonstration of high expression of AHR in lymphoid organs relative to other tissues are
consistent with a role for planar HAH in cetacean disease. As mechanisms for AHR-
dependent immunosuppression are discovered in rodent models, the potential for direct
examination for bona fide toxic responses in marine mammals increases.
There are several directions for future research that can immediately enhance
these studies. The first is to determine the inter- and intra-specific variability in AHR
ligand binding affinities among cetaceans and other highly exposed marine species.
Another need is to derive relative potencies for AHR-dependent responses that are
downstream from ligand-binding, such as nuclear translocation, DNA binding, and gene
induction. For example, DNA binding and/or gene induction might be measured in
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whole cells either by an endogenous enzyme such as CYPIA, or a reporter construct that
is driven by binding to dioxin-responsive elements.
This work is a part of efforts to address more general questions about the role of
the AHR in cetacean, mammalian, and overall environmental health. Some of these
include: What are the most critical toxic endpoints caused by HAH? What is the
likelihood of toxic effects to occur at doses observed in the environment? What are the
synergistic and antagonistic effects among different structure classes of HAH, or between
HAH with other contaminant types? What is the endogenous role of the AHR? Because
top-feeding marine mammals occupy a niche in the marine environment that is
comparable to the human niche in the terrestrial environment, understanding impacts in
marine mammals is critical for understanding the potential impacts on our own health.
Thus, it is important that these questions continue to be addressed with innovative
approaches and state-of-the art techniques.
In conclusion, this thesis provides critical evidence that cetaceans might be among
the most sensitive organisms to the effects of persistent planar halogenated aromatic
hydrocarbons and other AHR ligands. Future studies will continue to examine the
relevance of these in vitro relationships and toxic effects in the whole animal. Finally,
cloning and in vitro characterization of a key protein involved in toxicity is a promising
approach for obtaining species-specific mechanistic data from protected species.
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